

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number
WO 2004/080999 A1

(51) International Patent Classification⁷: C07D 401/12,
405/14, 401/14, 409/14, 409/12, 413/12, 231/14, A61K
31/4155, A61P 29/00

AB, P.O. Box 6280, S-102 34 Stockholm (SE). PEL-
CMAN, Benjamin [SE/SE]; Biolipox AB, P.O. Box 6280,
S-102 34 Stockholm (SE). SANIN, Andrei [RU/SE];
Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE).

(21) International Application Number:
PCT/GB2004/001054

(74) Agent: MCNEENEY, Stephen; Eric Potter Clarkson,
Park View House, 58 The Ropewalk, Nottingham NG1
5DD (GB).

(22) International Filing Date: 12 March 2004 (12.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0300705-1 14 March 2003 (14.03.2003) SE
60/482,563 26 June 2003 (26.06.2003) US

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except US, UZ): BI-
OLIPOX AB [SE/SE]; P.O. Box 6280, S-102 34 Stock-
holm (SE).

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

(71) Applicant (for UZ only): MCNEENEY, Stephen, Phillip
[GB/GB]; Park View House, 58 The Ropewalk, Notting-
ham NG1 5DD (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): HALLBERG,
Anders [SE/SE]; Department of Medicinal Chemistry,
Biomedical Centre, Uppsala University, P.O. Box 574,
S-751 23 Uppsala (SE). SCHAAL, Wesley [US/SE];
Biolipox AB, P.O. Box 6280, S-102 34 Stockholm (SE).
LARHED, Mats [SE/SE]; Department of Medicinal
Chemistry, Biomedical University, P.O. Box 574, S-751 23
Uppsala (SE). OLOFSSON, Kristofer [SE/SE]; Biolipox

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION



BEST AVAILABLE COPY

(I)

(57) Abstract: There is provided a compound of formula (I), wherein R¹, R², R³, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a lipooxygenase (e.g. 15-lipoxygenase) is desired and/or required, and particularly in the treatment of inflammation.

WO 2004/080999 A1

This Page Blank (uspto)

PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION

Field of the Invention

5

The invention relates to novel pharmaceutically-useful compounds. The invention further relates to compounds that are useful in the inhibition of the activity of 15-lipoxygenase and thus in the treatment of inflammatory diseases and of inflammation generally. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to synthetic routes for their production.

Background

15 There are many diseases/disorders that are inflammatory in their nature. One of the major problems associated with existing treatments of inflammatory conditions is a lack of efficacy and/or the prevalence of side effects (real or perceived).

20 Asthma is a chronic inflammatory disease affecting of 6% to 8% of the adult population of the industrialized world. In children, the incidence is even higher, being close to 10% in most countries. Asthma is the most common cause of hospitalization for children under the age of fifteen.

25 Treatment regimens for asthma are based on the severity of the condition. Mild cases are either untreated or are only treated with inhaled β -agonists. Patients with more severe asthma are typically treated with anti-inflammatory compounds on a regular basis.

There is a considerable under-treatment of asthma, which is due at least in part to perceived risks with existing maintenance therapy (mainly inhaled corticosteroids). These include risks of growth retardation in children and loss of bone mineral density, resulting in unnecessary morbidity and mortality. As an alternative to steroids, leukotriene receptor antagonists (LTRAs) have been developed. These drugs may be given orally, but are considerably less efficacious than inhaled steroids and usually do not control airway inflammation satisfactorily.

10 This combination of factors has led to at least 50% of all asthma patients being inadequately treated.

A similar pattern of under-treatment exists in relation to allergic disorders, where drugs are available to treat a number of common conditions but are underused in view of apparent side effects. Rhinitis, conjunctivitis and dermatitis may have an allergic component, but may also arise in the absence of underlying allergy. Indeed, non-allergic conditions of this class are in many cases more difficult to treat.

20 Chronic obstructive pulmonary disease (COPD) is a common disease affecting 6% to 8% of the world population. The disease is potentially lethal, and the morbidity and mortality from the condition is considerable. At present, there is no known pharmacological treatment capable of changing the course of COPD.

25 Other inflammatory disorders which may be mentioned include:

- (a) pulmonary fibrosis (this is less common than COPD, but is a serious disorder with a very bad prognosis. No curative treatment exists);

(b) inflammatory bowel disease (a group of disorders with a high morbidity rate. Today only symptomatic treatment of such disorders is available); and

(c) rheumatoid arthritis and osteoarthritis (common disabling inflammatory disorders of the joints. There are currently no curative, and only moderately effective symptomatic, treatments available for the management of such conditions).

Inflammation is also a common cause of pain. Inflammatory pain may arise for numerous reasons, such as infection, surgery or other trauma. Moreover, several malignancies are known to have inflammatory components adding to the symptomatology of the patients.

Thus, a new and/or alternative anti-inflammatory treatment would be of benefit to all of the above-mentioned patient groups. In particular, there is a real and substantial unmet clinical need for an effective anti-inflammatory drug capable of treating inflammatory disorders, such as asthma, with no real or perceived side effects.

The mammalian lipoxygenases are a family of structurally-related enzymes, which catalyze the oxygenation of arachidonic acid. Three types of human lipoxygenases are known, which catalyze the insertion of molecular oxygen into arachidonic acid at carbon positions 5, 12 and 15. The enzymes are thus named 5-, 12- and 15-lipoxygenase, respectively.

Arachidonic acid metabolites that are formed following the action of lipoxygenases are known to have pronounced pathophysiological activity including pro-inflammatory effects.

For example, the primary product of the action of 5-lipoxygenase on arachidonic acid is further converted by a number of enzymes to a variety of physiologically and pathophysiologically important metabolites. The most important of these, the leukotrienes, are strong bronchoconstrictors. Huge efforts have been devoted towards the development of drugs that inhibit the action of these metabolites as well as the biological processes that form them. Drugs that have been developed to this end include 5-lipoxygenase inhibitors, inhibitors of FLAP (Five Lipoxygenase Activating Protein) and, as mentioned previously, leukotriene receptor antagonists (LTRAs).

Another class of enzymes that metabolize arachidonic acid are the cyclooxygenases. Arachidonic acid metabolites that are produced by this process include prostaglandins, thromboxanes and prostacyclin, all of which possess physiological or pathophysiological activity. In particular, the prostaglandin PGE₂ is a strong pro-inflammatory mediator, which also induces fever and pain. Consequently, a number of drugs have been developed to inhibit the formation of PGE₂, including "NSAIDs" (non-steroidal antiinflammatory drugs) and "coxibs" (selective cyclooxygenase-2 inhibitors). These classes of compounds act predominantly by way of inhibition of one or several cyclooxygenases.

Thus, in general, agents that are capable of blocking the formation of arachidonic acid metabolites are likely to be of benefit in the treatment of inflammation.

Prior Art

Certain pyrazole compounds that are structurally related to those described herein are commercially available. However, to the knowledge of the


applicant, these compounds have never been disclosed in any printed publication and as such have no perceived utility ascribed to them.

Certain pyrazolecarboxylic acid hydrazides, structurally unrelated to the compounds described herein, have been disclosed as anti-inflammatory agents in Tihanyi *et al*, *Eur. J. Med. Chem. - Chim. Ther.*, 1984, 19, 433 and Goel *et al*, *J. Chem. Inf. Comput. Sci.* 1995, 35, 510.

Heterocyclic compounds (including pyrazoles) with anticonvulsant activity have been disclosed in US 5,258,397. Other heterocyclic compounds with antithrombotic activity have been disclosed in WO 02/00651. Neither of these documents discloses or suggests the use of the compounds disclosed therein in the treatment of inflammation.

15 Disclosure of the Invention

According to the invention there is provided a compound of formula I,



20

wherein

either

R¹ represents an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G¹ and B¹,

25

which B¹ group may itself be further substituted by one or more substituents selected from G², Z (provided that Z is not directly attached to an aryl or a heteroaryl group) and B² (which B² group is optionally further substituted by one or more substituents selected from G³, B³ and Z, provided that Z is not attached to an aryl or a heteroaryl group); and

R² represents H or C₁₋₆ alkyl, which latter group is optionally substituted by one or more halo groups;

or

when R² represents C₁₋₆ alkyl optionally substituted by halo, R¹ and R² may be linked together forming a further 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more substituents selected from G¹, Z (provided that the ring is not aromatic in nature) and B¹ (which B¹ group is optionally substituted as described above);

R³ represents C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ heterocycloalkyl, aryl or heteroaryl, all of which groups are optionally substituted by one or more substituents selected from G^{1a}, Z (provided that Z is not directly attached to an aryl or a heteroaryl group) and B¹ (which B¹ group is optionally substituted as described above);

X represents a direct bond, -O- or -N(R⁴)-;

Y represents -C(O)-, -C(S)- or -S(O)₂-;

B¹, B² and B³ independently represent, on each occasion when used above, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cycloalkyl, C₃₋₈ heterocycloalkyl, aryl or heteroaryl;

G^1 , G^{1a} , G^2 and G^3 independently represent, on each occasion when used above, halo, cyano, $-N_3$, $-NO_2$, $-ONO_2$ or $-A^1-R^4$;

wherein A^1 represents a spacer group selected from $-C(Z)A^2-$, $-N(R^5)A^3-$, $-OA^4-$, $-S-$ or $-S(O)_nA^5-$, in which:

5 A^2 represents a single bond, $-O-$, $-S-$ or $-N(R^5)-$;

A^3 represents A^6 , $-C(Z)N(R^5)C(Z)N(R^5)-$, $-C(Z)N(R^5)C(Z)O-$, $-C(Z)N(R^5)S(O)_nN(R^5)-$, $-C(Z)S-$, $-S(O)_n-$, $-S(O)_nN(R^5)C(Z)N(R^5)-$, $-S(O)_nN(R^5)C(Z)O-$, $-S(O)_nN(R^5)S(O)_nN(R^5)-$, $-C(Z)O-$, $-S(O)_nN(R^5)-$ or $-S(O)_nO-$;

10 A^4 represents A^6 , $-S(O)_n-$, $-C(Z)O-$, $-S(O)_nN(R^5)-$ or $-S(O)_nO-$;

A^5 represents a single bond, $-N(R^5)-$ or $-O-$;

A^6 represents a single bond, $-C(Z)-$ or $-C(Z)N(R^5)-$;

15 Z represents, on each occasion when used above, a substituent connected by a double bond, which is selected from $=O$, $=S$, $=NR^4$, $=NN(R^4)(R^5)$, $=NOR^4$, $=NS(O)_2N(R^4)(R^5)$, $=NCN$, $=CHNO_2$ and $=C(R^4)(R^5)$;

20 R^4 and R^5 independently represent, on each occasion when used above, H or B^4 , which B^4 group is itself optionally substituted by one or more substituents selected from G^4 , Q (provided that Q is not directly attached to an aryl or a heteroaryl group) and B^5 (which B^5 group is itself optionally substituted by one or more substituents selected from G^5 , Q (provided that Q is not directly attached to an aryl or a heteroaryl group) and B^6); or

25 when R^4 and R^5 both represent optionally substituted B^4 groups, then any pair thereof may, for example when present on the same atom or on adjacent atoms, be linked together to form, with those, or other relevant atoms, a 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more substituents selected from G^6 , Q (provided that the ring is not

aromatic in nature) and B^4 (which B^4 group is optionally substituted as described above);

B^4 , B^5 and B^6 independently represent on each occasion when used above
 5 C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, aryl or heteroaryl;

G^4 , G^5 and G^6 independently represent on each occasion when used above, halo, cyano, N_3 , $-NO_2$, $-ONO_2$ or $-A^7-R^6$;

10 wherein A^7 represents a spacer group selected from $-C(Q)A^8-$, $-N(R^7)A^9-$, $-N(R^{7a})A^{9a}-$, $-OA^{10}-$, $-S-$ or $-S(O)_nA^{11}-$, in which:

A^8 represents a single bond, $-O-$, $-S-$ or $-N(R^7)-$;

A^9 represents A^{12} , $-C(Q)S-$, $-S(O)_n-$, $-C(Q)O-$, $-S(O)_nN(R^7)-$ or $-S(O)_nO-$;

A^{9a} represents $-C(Q)N(R^7)C(Q)N(R^7)-$, $-C(Q)N(R^7)C(Q)O-$,
 15 $-C(Q)N(R^7)S(O)_nN(R^7)-$, $-S(O)_nN(R^7)C(Q)N(R^7)-$, $-S(O)_nN(R^7)C(Q)O-$,
 $-S(O)_nN(R^7)S(O)_nN(R^7)-$;

A^{10} represents A^{12} , $-S(O)_n-$, $-C(Q)O-$, $-S(O)_nN(R^7)-$ or $-S(O)_nO-$;

A^{11} represents a single bond, $-N(R^7)-$ or $-O-$;

A^{12} represents a single bond, $-C(Q)-$ or $-C(Q)N(R^7)-$;

20

Q represents, on each occasion when used above, a substituent connected by a double bond, which is selected from $=O$, $=S$, $=NR^6$, $=NN(R^6)(R^7)$, $=NOR^6$, $=NS(O)_2N(R^6)(R^7)$, $=NCN$, $=CHNO_2$ and $=C(R^6)(R^7)$;

25 R^6 , R^7 and R^{7a} independently represent, on each occasion when used above, H , C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, aryl or heteroaryl, which latter seven groups are optionally substituted by one or more groups selected from halo, C_{1-6} alkyl

(optionally substituted by one or more halo groups), $-N(R^8)R^9$, $-OR^8$, $-ONO_2$ and $-SR^8$; or

provided that they do not represent H, any pair of R^6 and R^7 may, for example when present on the same atom or on adjacent atoms, be linked together to form, with those, or other relevant, atoms, a 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more groups selected from halo, C_{1-6} alkyl (optionally substituted by one or more halo groups), $-N(R^8)R^9$, $-OR^8$, $-ONO_2$ and $-SR^8$;

R^8 and R^9 independently represent, on each occasion when used above, H or C_{1-6} alkyl, which latter group is optionally substituted by one or more halo groups; and

n represents, on each occasion when used above, 1 or 2;

or a pharmaceutically-acceptable salt thereof,

provided that, when R^2 represents H, Y represents $-C(O)-$ and:

(A) X represents a direct bond and:

- i) R^3 represents phenyl, then R^1 does not represent phenyl, 2-methoxyphenyl, 2-thiazolyl or 6-methyl-2-pyridinyl;
- ii) R^3 represents 4-fluorophenyl, then R^1 does not represent 2-carbomethoxyphenyl, 3-carbomethoxyphenyl or 2,4-dimethylphenyl;
- iii) R^3 represents 2-chlorophenyl, then R^1 does not represent phenyl, 3-bromophenyl or 4-bromophenyl;

iv) R^3 represents 3-chlorophenyl, then R^1 does not represent phenyl, 2-fluorophenyl, 2-chlorophenyl, 2,3-dichlorophenyl or 2,5-dichlorophenyl;

v) R^3 represents 4-chlorophenyl, then R^1 does not represent 3-bromophenyl or 4-methoxyphenyl;

vi) R^3 represents 3-iodophenyl, then R^1 does not represent 2-methoxyphenyl or 2,4-dimethylphenyl;

vii) R^3 represents 2,4-dichlorophenyl, then R^1 does not represent 4-chlorophenyl or 2,3-dichlorophenyl;

viii) R^3 represents 3,5-dinitrophenyl, then R^1 does not represent 2,3-dichlorophenyl;

ix) R^3 represents 2,4-dimethyl-6-oxo-6H-pyran-3-yl, then R^1 does not represent 3-carbomethoxyphenyl;

x) R^3 represents methyl, then R^1 does not represent 3,4-dichlorophenyl, 2-methoxyphenyl, 2-thiazolyl, 4-methyl-2-pyridinyl, 6-methyl-2-pyridinyl or 4-acetylphenyl;

xi) R^3 represents ethyl, then R^1 does not represent phenyl, 2,3-dichlorophenyl, 4-methoxyphenyl, 2-carbomethoxyphenyl, 2-thiazolyl or 4-methyl-2-pyridinyl;

(B) X represents -N(H)- and:

i) R^3 represents phenyl, then R^1 does not represent 4-methoxyphenyl, 2,4-dimethylphenyl or 2-thiazolyl;

ii) R^3 represents 3-chlorophenyl, then R^1 does not represent 4-methylphenyl;

iii) R^3 represents 4-chlorophenyl, then R^1 does not represent 3-bromophenyl;

iv) R^3 represents 3,4-dichlorophenyl, then R^1 does not represent 4-methyl-2-pyridinyl or 6-methyl-2-pyridinyl;

- v) R^3 represents 2'-sulfamoylbiphenyl-4-yl, then R^1 does not represent 5-bromo-2-pyridinyl;
- vi) R^3 represents 1-propyl, then R^1 does not represent phenyl;
- vii) R^3 represents 1-butyl, then R^1 does not represent 4-bromophenyl or 2,4-dimethylphenyl;
- viii) R^3 represents cyclohexyl, then R^1 does not represent 4-methoxyphenyl;

(C) X represents -O- and:

- i) R^3 represents phenyl, then R^1 does not represent phenyl or 6-methyl-2-pyridinyl;
- ii) R^3 represents methyl, then R^1 does not represent phenyl, 2-fluorophenyl, 2,4-dimethylphenyl, 4-acetylphenyl or 2-thiazolyl;
- iii) R^3 represents ethyl, then R^1 does not represent phenyl, 2-fluorophenyl, 4-acetylphenyl or 4-methyl-2-pyridinyl;
- iv) R^3 represents 1-butyl, then R^1 does not represent 2-fluorophenyl, 2-methoxyphenyl, 4-methyl-2-pyridinyl or 6-methyl-2-pyridinyl;
- v) R^3 represents 2-butyl, then R^1 does not represent 2-thiazolyl or 4-acetylphenyl;
- vi) R^3 represents 2-methyl-1-propyl, then R^1 does not represent phenyl or 3-nitrophenyl,

which compounds and salts are referred to hereinafter as "the compounds of the invention".

Pharmaceutically-acceptable salts include acid addition salts and base addition salts. Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of the

invention with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. *in vacuo*, by freeze-drying or by filtration). Salts may also
5 be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

Compounds of formula I may contain double bonds and may thus exist as *E*
10 (*entgegen*) and *Z* (*zusammen*) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.

Compounds of formula I may also exhibit tautomerism. All tautomeric
15 forms and mixtures thereof are included within the scope of the invention.

Compounds of formula I may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g.
20 chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by
25 reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means (e.g. HPLC, chromatography over silica). All stereoisomers and mixtures thereof are included within the scope of the invention.

Unless otherwise specified, C_{1-q} alkyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain. C_{1-6} alkyl groups that may be mentioned include methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, isopentyl, *n*-hexyl, and isohexyl.

C_{2-q} alkenyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched-chain. Such alkenyl groups may contain one or more double bonds. C_{2-6} -alkenyl groups that may be mentioned include vinyl, 1-propenyl, 2-propenyl, propadienyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 1-pentenyl, 2-pentenyl, 4-pentenyl, and 5-hexenyl.

C_{2-q} alkynyl groups (where q is the upper limit of the range) defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, be branched-chain. Such alkynyl groups may contain one or more triple bonds. C_{2-6} -alkynyl groups that may be mentioned include ethynyl, 1-propynyl, 2-propynyl, 1-butyne, 2-butyne, 3-butyne, 1-pentyne, 2-pentyne, 4-pentyne, 1-hexynyl, 3-hexynyl, and 5-hexynyl.

C_{3-q} cycloalkyl groups (where q is the upper limit of the range) that may be mentioned include monocyclic or bicyclic alkyl groups. Such cycloalkyl groups may be saturated or unsaturated containing one or more double or triple bond (forming for example a C_{3-q} cycloalkenyl or a C_{3-q} cycloalkynyl group). C_{3-8} -cycloalkyl groups that may be mentioned include cyclopropyl,

cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclooctynyl, bicycloheptyl, bicyclooctyl, and bicyclooctenyl. Substituents may be attached at any point on the cycloalkyl group. Further in the case where the substituent is another
5 cyclic compound, then the cyclic substituent may be attached through a single atom on the cycloalkyl group, forming a so-called "spiro"-compound.

C_{3-q} heterocycloalkyl groups (where q is the upper limit of the range) that may be mentioned include monocyclic or bicyclic alkyl groups in which at
10 least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom). Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C_{3-q} heterocycloalkenyl or a C_{3-q} heterocycloalkynyl group. C_{3-q} heterocycloalkyl groups that may be mentioned include
15 aziridinyl, azetidiny, dihydropyranyl, dihydropyridinyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxanyl (including 1,3-dioxanyl and 1,4-dioxanyl), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), imidazolidinyl, imidazolinyl, morpholinyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl,
20 pyranyl, pyrazolidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolanyl, 3-sulfolenyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridinyl, thietanyl, thiiranyl, thiolanyl, thiomorpholinyl, trithianyl (including 1,3,5-trithianyl), tropanyl and the like. Substituents on the heterocycloalkyl groups may, where appropriate, be located on any atom
25 in the ring system including a heteroatom. Further in the case where the substituent is another cyclic compound, then the cyclic substituent may be attached through a single atom on the heterocycloalkyl group, forming a so-called "spiro"-compound. The point of attachment of a heterocycloalkyl group may be *via* any atom in the ring system including (where appropriate)

a heteroatom, or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heterocycloalkyl groups may also be in the *N*- or *S*-oxidised form.

- 5 The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.

Aryl groups that may be mentioned include C₆₋₁₀ aryl groups. Such groups may be monocyclic or bicyclic and have between 6 and 10 ring carbon atoms, in which at least one ring is aromatic. C₆₋₁₀ aryl groups include
10 phenyl, naphthyl and the like, such as 1,2,3,4-tetrahydronaphthyl, indanyl, and indenyl. The point of attachment of aryl groups may be *via* any atom of the ring system.

Heteroaryl groups that may be mentioned include those which have between
15 5 and 10 members. Such groups may be monocyclic, bicyclic or tricyclic, in which at least one of the rings is aromatic and wherein at least one (e.g.

one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom). Heterocyclic groups that may be mentioned include acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including
20 1,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiazolyl (including 2,1,3-benzothiazolyl), benzoxadiazolyl (including 2,1,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2*H*-1,4-benzoxazinyl), benzoxazolyl, benzimidazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1,3-benzoselenadiazolyl),
25 benzothiophenyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazo[1,2-*a*]pyridinyl, indazolyl, indolinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, naphthyridinyl (including 1,5-naphthyridinyl and 1,8-naphthyridinyl), oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl

and 1,3,4-oxadiazolyl), oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinoliny, quinoliziny, quinoxaliny, tetrahydroisoquinoliny, tetrahydroquinoliny, tetrazolyl, thiadiazolyl (including 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl and 1,3,4-thiadiazolyl), thiazolyl, thiochromanyl, thiophenyl, triazolyl (including 1,2,3-triazolyl, 1,2,4-triazolyl and 1,3,4-triazolyl) and the like. Substituents on heteroaryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heteroaryl groups may be *via* any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heteroaryl groups may also be in the *N*- or *S*- oxidised form.

- 15 Heteroatoms that may be mentioned include oxygen, nitrogen, sulphur and selenium.

For the avoidance of doubt, in cases in which the identity of two or more substituents in a compound of formula I may be the same, the actual identities of the respective substituents are not in any way interdependent. For example, in the situation in which R^1 and R^3 are both aryl groups substituted by one or more C_{1-6} alkyl groups, the alkyl groups in question may be the same or different. Similarly, when groups are substituted by more than one substituent as defined herein, the identities of those individual substituents are not to be regarded as being interdependent.

Compounds of the invention that may be mentioned include those of formula I, and pharmaceutically-acceptable salts thereof, in which any one,

or more (including all), of the specific compounds that are excluded by way of the above provisos are not so excluded.

Compounds that may be mentioned include those in which B^4 , R^6 and/or R^7 do not represent a heteroaryl group.

Preferred compounds of the invention include those in which:

R^1 represents an aryl or heteroaryl group, both of which are optionally substituted as hereinbefore defined;

10 G^1 represents halo, cyano or $-A^1-R^4$;

G^{1a} represents halo, cyano, $-NO_2$ or $-A^1-R^4$;

G^2 represents halo, cyano, $-ONO_2$ or $-A^1-R^4$;

B^2 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which are optionally substituted by one or more G^3 and/or B^3 groups;

15 G^3 represents halo, $-ONO_2$, $-N(R^5)(R^4)$ or $-OR^4$;

B^3 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

when A^1 represents $-N(R^5)A^3-$, A^3 represents A^6 , $-C(Z)S-$, $-S(O)_n-$, $-C(Z)O-$ or $-S(O)_nN(R^5)-$;

when A^1 represents $-OA^4-$, A^4 represents A^6 ;

20 when A^1 represents $-S(O)_nA^5-$, A^5 represents a single bond or $-N(R^5)-$;

Z represents $=O$ or $=NR^4$;

when any pair of R^4 and R^5 are linked together to form a ring, they are optionally substituted with G^6 and/or B^4 ;

G^4 represents halo, cyano, $-ONO_2$ or $-A^7-R^6$;

25 B^5 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which are optionally substituted by one or more G^5 and/or B^6 groups;

G^5 represents halo, $-ONO_2$, $-N(R^7)(R^6)$ or $-OR^6$;

B^6 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

G^6 represents halo, cyano or $-A^7-R^6$;

A^7 represents $-C(Q)A^8-$, $-N(R^7)A^9-$, $-OA^{10}-$, $-S-$ or $-S(O)_nA^{11}-$;

when A^7 represents $-N(R^7)A^9-$, A^9 represents A^{12} , $-C(Q)S-$, $-S(O)_n-$, $-C(Q)O-$ or $-S(O)_nN(R^7)-$;

when A^7 represents $-OA^{10}-$, A^{10} represents A^{12} ;

5 when A^7 represents $-S(O)_nA^{11}-$, A^{11} represents a single bond or $-N(R^7)-$;

Q represents $=O$ or $=NR^6$;

R^6 , R^7 and R^{7a} independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which groups are optionally substituted by one or more groups selected from halo, C_{1-6} alkyl, $-N(R^8)R^9$, OR^8 and $-ONO_2$; and/or

10 when any pair of R^6 and R^7 are linked together to form a ring, that ring is optionally substituted by one or more groups selected from halo, C_{1-6} alkyl (optionally substituted by one or more halo groups), $-N(R^8)R^9$, $-OR^8$ and $-ONO_2$.

15 More preferred compound include those in which:

B^1 represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{4-7} heterocycloalkyl, or phenyl, group, all of which are optionally substituted as described hereinbefore;

G^2 represents halo (e.g. fluoro or chloro);

20 B^2 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which are optionally substituted by one or more halo groups;

when A^1 represents $-C(Z)A^2-$, A^2 represents a single bond, $-O-$ or $-N(R^5)-$;

when A^1 represents $-N(R^5)A^3-$, A^3 represents A^6 ;

when A^1 represents $-S(O)_nA^5$, A^5 represents a single bond;

25 A^6 represents a single bond;

Z represents $=O$;

B^4 represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{4-7} heterocycloalkyl, or phenyl, group, all of which are optionally substituted as described hereinbefore;

G^4 represents halo;

B^5 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which groups are optionally substituted by one or more halo groups;

when A^7 represents $-C(Q)A^8-$, A^8 represents a single bond, $-O-$ or $-N(R^7)-$;

5 when A^7 represents $-N(R^7)A^9-$, A^9 represents A^{12} ;

when A^7 represents $-S(O)_nA^{11}$, A^{11} represents a single bond;

A^{12} represents a single bond;

Q represents $=O$.

10 Further preferred compounds include those in which:

B^4 represents C_{2-6} alkenyl, C_{2-6} alkynyl or, preferably, C_{1-6} alkyl;

G^6 represents halo;

R^6 , R^7 and/or R^{7a} represent H, C_{1-6} alkyl optionally substituted by one or more halo groups.

15

Further preferred compounds include those in which:

R^4 and/or R^5 independently represent H or C_{1-6} alkyl, which latter group is optionally substituted by one or more fluoro groups.

20 Further preferred compounds include those in which:

B^1 represents a C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{5-6} heterocycloalkyl, or phenyl, group, all of which are optionally substituted as described hereinbefore;

G^{1a} represents halo, $-NO_2$ or $-A^1-R^4$;

25 A^1 represents $-C(Z)A^2-$, $-N(R^5)A^3-$ and $-OA^4-$;

when A^1 represents $-C(Z)A^2-$, A^2 represents a single bond or $-O-$.

Preferred compounds of the invention include those in which R^1 represents an optionally substituted phenyl, naphthyl, pyrrolidinyl, piperidinyl,

pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl (e.g. 2-pyridinyl, 3-pyridinyl or 4-pyridinyl), indazolyl, indolyl, indolinyl, isoindolinyl, oxindolyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinoliziny, benzofuranyl, isobenzofuranyl, chromanyl, benzothiophenyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, quinazolinyl, quinoxalinyl, 1,3-benzodioxolyl, benzothiazolyl, and/or benzodioxanyl, group. It is preferred in the above list that R¹ does not represent naphthyl, pyrrolidinyl, piperidinyl, indazolyl, oxindolyl or benzothiazolyl. Particularly preferred values of R¹ include optionally substituted phenyl, pyridinyl (especially 2- and 3-pyridinyl), thiophenyl (especially 2-thiophenyl), pyrazolyl (especially 4-pyrazolyl), isoxazolyl (especially 5-isoxazolyl), benzodioxolyl (especially 1,3-benzodioxolyl), indazolyl, benzothiazolyl, and quinolinyl, groups.

15

Such R¹ groups are optionally substituted by one or more substituents selected from:

halo (e.g. fluoro, chloro or bromo);

cyano;

C₁₋₆ alkyl, which alkyl group may be linear or branched (e.g. C₁₋₄ alkyl (including methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *s*-butyl, *i*-butyl or *t*-butyl), *n*-pentyl, *i*-pentyl, *n*-hexyl or *i*-hexyl), substituted by one or more fluoro group (e.g. -CH₂F, -CHF₂ or -CF₃), and/or substituted by a C₃₋₆ cycloalkyl (e.g. cyclopropyl) group, so forming, for example, a cyclopropylmethyl group;

C₂₋₆ alkenyl (e.g. 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 4-pentenyl or 5-hexenyl);

C₃₋₆ cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl);

phenyl;

a heterocyclic group selected from a pyrrolidinyl (including 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), a piperidinyl (including 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl and 1-methyl-4-piperidinyl), a piperazinyl (including 1-piperazinyl and 4-methyl-1-piperazinyl), a tetrahydrofuranyl (including 2-tetrahydrofuranyl and 3-tetrahydrofuranyl), a tetrahydropyranyl (including 1-tetrahydropyranyl, 2-tetrahydropyranyl and 3-tetrahydropyranyl), or a 4-morpholinyl, group;

thiomethyl, methylsulfinyl, methylsulfonyl;

-OR¹⁰;

10 -N(R¹⁰)R¹¹;

-C(O)OR¹⁰;

-C(O)R¹⁰;

-C(O)N(R¹⁰)R¹¹;

-S(O)₂N(R¹⁰)R¹¹; and/or

15 -N(R¹⁰)S(O)₂R¹²;

wherein R¹⁰ and R¹¹ independently represent, on each occasion when used above, H, phenyl, C₁₋₆ alkyl (such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *t*-butyl), which alkyl group is optionally substituted by one or more fluoro atom, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl; or

20 R¹⁰ and R¹¹ may be linked together to form, with the nitrogen atom to which they are attached, a 5- to 7-membered ring, optionally containing one additional heteroatom and optionally substituted with one or more C₁₋₆ alkyl groups, which alkyl groups are themselves optionally substituted by one or more halo (e.g. fluoro) groups (for example a morpholine, a piperazine, or a 4-methylpiperazine, group); and

25 R¹² represents phenyl, C₁₋₆ alkyl (such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *t*-butyl), which alkyl group is optionally substituted by one or more fluoro atom, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl.

When one or more of the above optional substituents on R^1 represents:

-OR¹⁰, then R¹⁰ is preferably H, methyl (optionally substituted by 1 to 3 fluoro atoms, e.g. CF₃), ethyl, *n*-propyl or *i*-propyl;

-N(R¹⁰)R¹¹, then R¹⁰ is preferably H, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *t*-butyl and/or R¹¹ is preferably H, methyl or ethyl;

-C(O)OR¹⁰, then R¹⁰ is preferably methyl, ethyl or *i*-propyl;

-C(O)R¹⁰, then R¹⁰ is preferably methyl, ethyl or *t*-butyl;

-C(O)N(R¹⁰)R¹¹ or -S(O)₂N(R¹⁰)R¹¹, then R¹⁰ and R¹¹ are preferably H or methyl;

-N(R¹⁰)S(O)₂R¹², then R¹⁰ is preferably H or methyl and R¹² is preferably methyl.

Particularly preferred optional substituents on R¹ include carbomethoxy, methyl, dimethylamino, cyano, chloro, fluoro, trifluoromethyl, bromo, methoxy and trifluoromethoxy.

Preferred compounds of the invention include those in which R³ represents an optionally substituted C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl (especially 4-piperidinyl), piperazinyl (especially 4-piperazinyl), pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl (e.g. 2-pyridinyl, 3-pyridinyl or 4-pyridinyl), indazolyl, indolyl, indolinyl, isoindolinyl, oxindolyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinolizinyl, benzofuranyl, isobenzofuranyl, chromanyl, benzothiophenyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, quinazolinyl, quinoxalinyl, 1,3-benzodioxolyl, benzothiazolyl and/or benzodioxanyl group. Particularly preferred groups include an optionally substituted C₁₋₆ alkyl (such as methyl, pentyl or hexyl), cyclohexyl, phenyl, thiophenyl (especially 2-thiophenyl), furanyl (especially 2-furanyl and 3-

furanyl), pyrrolyl (especially 2-pyrrolyl), naphthyl (especially 1-naphthyl), benzofuranyl, piperazinyl (especially 4-piperazinyl), piperidinyl (especially 4-piperidinyl), or benzodioxolyl (especially 1,3-benzodioxolyl), group.

5 Such R³ groups are optionally substituted by one or more substituents selected from:

halo;

-NO₂;

cyano;

10 C₁₋₆ alkyl, which alkyl group may be linear or branched (e.g. C₁₋₄ alkyl (including methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *s*-butyl, *i*-butyl or *t*-butyl), *n*-pentyl, *i*-pentyl, *n*-hexyl or *i*-hexyl), substituted by one or more halo (e.g. fluoro) group (e.g. -CH₂F, -CHF₂ or -CF₃), C₁₋₆ alkyl group (e.g. methyl or ethyl), C₂₋₆ alkenyl group or C₃₋₆ cycloalkyl group (e.g. cyclopropylmethyl, so forming, for example, a cyclopropylmethyl group),
15 which latter three groups are themselves optionally substituted with one or more halo (e.g. fluoro) and/or C₁₋₆ alkyl groups;

C₂₋₆ alkenyl (e.g. 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 4-pentenyl or 5-hexenyl), optionally substituted with
20 one or more C₁₋₆ alkyl groups;

C₃₋₆ cycloalkyl (e.g. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), optionally substituted with one or more halo (e.g. fluoro) group; phenyl, optionally substituted with one or more halo (e.g. fluoro or, especially, chloro) groups;

25 a heterocyclic group selected from a pyrrolidinyl (including 1-pyrrolidinyl, 2-pyrrolidinyl and 3-pyrrolidinyl), a piperidinyl (including 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl and 1-methyl-4-piperidinyl), a piperazinyl (including 1-piperazinyl and 4-methyl-1-piperazinyl), a tetrahydrofuranyl (including 2-tetrahydrofuranyl and 3-tetrahydrofuranyl), a

tetrahydropyranyl (including 1-tetrahydropyranyl, 2-tetrahydropyranyl and 3-tetrahydropyranyl), or a 4-morpholinyl, group;
thiomethyl, methylsulfinyl, methylsulfonyl;

=O;

5 -OR¹³;

-N(R¹³)R¹⁴;

-C(O)OR¹³;

-C(O)R¹³;

-C(O)N(R¹³)R¹⁴;

10 -S(O)₂N(R¹³)R¹⁴; and/or

-N(R¹³)S(O)₂R¹⁵;

wherein R¹³ and R¹⁴ independently represent, on each occasion when used above, H, phenyl, C₁₋₆ alkyl (such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *t*-butyl) which alkyl group is optionally substituted by one or more

15 fluoro atom, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl; or

R¹³ and R¹⁴ may be linked together to form, with the nitrogen atom to which they are attached, a 5- to 7-membered ring, optionally containing one additional heteroatom and optionally substituted with one or more C₁₋₆ alkyl groups, which alkyl groups are themselves optionally substituted by one or
20 more halo (e.g. fluoro) groups (for example a morpholine, a piperazine, or a 4-methylpiperazine, group); and

R¹⁵ represents phenyl, C₁₋₆ alkyl (such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *t*-butyl), which alkyl group is optionally substituted by one or more fluoro atom, C₂₋₆ alkenyl or C₃₋₆ cycloalkyl.

25

When one or more of the above optional substituents on R³ represents:

-OR¹³, then R¹³ is preferably H, methyl (optionally substituted by 1 to 3 fluoro atoms, e.g. -CF₃), ethyl, *n*-propyl or *i*-propyl;

- N(R¹³)R¹⁴, then R¹³ is preferably H, methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl or *i*-butyl and/or R¹⁴ is preferably H, methyl or ethyl;
- C(O)OR¹³, then R¹³ is preferably methyl, ethyl or *i*-propyl;
- C(O)R¹³, then R¹³ is preferably methyl, -CF₃, ethyl or *i*-butyl;
- 5 -C(O)N(R¹³)R¹⁴ or -S(O)₂N(R¹³)R¹⁴, then R¹³ and R¹⁴ are preferably H or methyl;
- N(R¹³)S(O)₂R¹⁵, then R¹³ is preferably H or methyl and R¹⁵ is preferably methyl.
- 10 When R³ represents C₁₋₆ alkyl or C₂₋₆ alkenyl substituted by other alkyl or alkenyl groups (which may be further substituted by alkyl/alkenyl, as indicated above), groups that may be mentioned include 1-octyl, 1-tridecanyl, 1-pentadecanyl, 1-heptadecanyl, 1-heptadec-8-enyl, 1-heptadeca-8,11-dienyl, 1-heptadeca-8,11,14-trienyl and 1-nonadeca-
- 15 4,7,10,13-tetraenyl groups.

Particularly preferred optional substituents on R³ include methyl, ethyl, ethoxy, trifluoromethyl, fluoro, chloro, iodo, phenyl, chlorophenyl (such as 2-chlorophenyl and 4-chlorophenyl), *n*-pentyl, *i*-propyl, nitro, *t*-butyl,

20 -CH₂CH=CHC₈H₁₇, trifluoroacetyl, carbomethoxy, carboethoxy and trifluoromethoxy.

Further preferred compounds of the invention include those in which:

R² represents H or C₁₋₃ alkyl;

25 X represents a direct bond, -O-, -N(H)- or -N(Me)-.

More preferred values of R² include H, methyl and ethyl, particularly H or methyl.

Compounds of the invention that may also be mentioned include those in which:

5 R^1 is phenyl, 2-chlorophenyl, 2-chloro-4-fluorophenyl, 3-chloro-4-fluorophenyl, 2,6-dichlorophenyl, 5-chloro-2-cyanophenyl, 2-fluoro-5-trifluoromethylphenyl, 2-bromo-4-trifluoromethoxyphenyl, 2-methoxy-6-methylphenyl, 3-cyanophenyl, 4-trifluoromethylphenyl, 4-dimethylaminophenyl, 4-carbomethoxyphenyl, 1,3,5-trimethyl-1*H*-pyrazol-4-yl, 3-methylisoxazol-5-yl, 3-pyridinyl, 2-chloro-3-pyridinyl, 3-methyl-2-pyridinyl, 3-carbomethoxythiophen-2-yl or 1,3-benzodioxolyl;

10 R^2 is hydrogen or methyl;

R^3 is methyl, *n*-butyl, *n*-pentyl, 1-octyl, oleoyl, (1*R*,2*S*,5*R*)-(-)-menthyl, 2-chlorobenzyl, benzyl, phenyl, 3-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluoro-5-iodophenyl, 5-fluoro-2-methylphenyl, 4-*tert*-butylphenyl, 4-pentylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 15 4-nitrophenyl, 2-ethoxyphenyl, 1-naphthyl, 2-furanyl, 2,5-dimethyl-3-furanyl, 2-carbomethoxy-5-furanyl, 1-methyl-1*H*-pyrrol-2-yl, 3-methyl-2-benzofuranyl, 3-methyl-2-thiophenyl, 1(*N*)-methyl-4-piperazinyl, 1(*N*)-(2,2,2-trifluoroacetyl)piperidin-4-yl, ethylhexanoate or 1,3-benzodioxolyl;

Y is -C(O)-, -C(S)- or -S(O)₂-; and

20 X is a bond, -N(H)-, -N(Me)-, or -O-.

Further compounds of the invention that may also be mentioned include those in which:

25 R^1 is 2-chlorophenyl, 5-chloro-2-cyanophenyl, 4-dimethylaminophenyl, 4-carbomethoxyphenyl, 1,3,5-trimethyl-1*H*-pyrazol-4-yl, 3-methylisoxazol-5-yl, 3-pyridinyl, or 3-carbomethoxythien-2-yl;

R^2 is hydrogen or methyl;

R^3 is methyl, 1-octyl, oleoyl, (1*R*,2*S*,5*R*)-(-)-menthyl, 2-chlorobenzyl, phenyl, 3-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluoro-5-

iodophenyl, 5-fluoro-2-methylphenyl, 4-*tert*-butylphenyl, 4-pentylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 2-ethoxyphenyl, 1-naphthyl, 2-furanyl, 2,5-dimethyl-3-furanyl, 2-carbomethoxy-5-furanyl, 1-methyl-1*H*-pyrrol-2-yl, 3-methyl-2-benzofuranyl, or 3-methyl-2-thiophenyl;


- 5 Y is $-\text{C}(\text{O})-$, $-\text{C}(\text{S})-$ or $-\text{S}(\text{O})_2-$; and
 X is a bond, $-\text{N}(\text{H})-$, $-\text{N}(\text{Me})-$, or $-\text{O}-$.

Particularly preferred compounds of the invention include those of the examples described hereinafter.

- 10 Compounds of formula I may be made in accordance with techniques that are well known to those skilled in the art, for example as described hereinafter.


- 15 According to a further aspect of the invention there is provided a process for the preparation of a compound of formula I, which process comprises:

- (i) for compounds of formula I in which, when Y is $-\text{S}(\text{O})_2-$, X represents a direct bond or $-\text{N}(\text{R}^4)-$, in which R^4 represents B^4 , reaction of a compound
 20 of formula II,



wherein R^1 and R^2 are as hereinbefore defined, with a compound of formula

- 25 III,



III

wherein X^a represents a direct bond or $-N(B^4)-$ when Y represents $-S(O)_2-$ or, for all other values of Y, represents X as hereinbefore defined, R^3 and Y are as hereinbefore defined and L^1 represents a suitable leaving group, such as halo (e.g. chloro or bromo), or, when X^a is a direct bond, a carboxylate (e.g. a $-O-C(O)-R^3$) group or a sulfonylate (e.g. a $-O-S(O)_2-R^3$) group, or, when X^a is $-N(B^4)-$, an N-imidazolyl group, for example at around room temperature or above (e.g. up to 40-180°C) in the presence of a suitable base (e.g. sodium hydride, sodium bicarbonate, potassium carbonate, pyrrolidinopyridine, pyridine, triethylamine, tributylamine, trimethylamine, dimethylaminopyridine, di-*iso*-propylamine, 1,8-diazabicyclo[5.4.0]undec-7-ene, sodium hydroxide, *N*-ethyl-di-*iso*-propylamine, *N*-(methylpolystyrene)-4-(methylamino)pyridine or mixtures thereof) and an appropriate solvent (e.g. tetrahydrofuran, pyridine, toluene, dichloromethane, chloroform, dimethylformamide, trifluoromethylbenzene or triethylamine). Preferred base/solvent systems for compounds of formula III in which Y is $-C(O)-$ and X is a direct bond include sodium hydride in tetrahydrofuran, DMF or mixtures thereof. Preferred base/solvent systems for compounds of formula III in which Y is $-C(O)-$ and X^a is $-O-$ or $-NR^4-$ or when Y is $-S(O)_2-$ and X^a is a direct bond include dimethylaminopyridine/dichloromethane, or a mixture of triethylamine and dimethylaminopyridine in dichloromethane;

(ii) for compounds of formula I in which X represents a single bond and Y represents $-C(O)-$, reaction of a compound of formula II as hereinbefore defined with a compound of formula IV,



IV

wherein R^3 is as hereinbefore defined for example under similar conditions to those described under process step (i) above, in the presence of a suitable coupling reagent (e.g. 1,1'-carbonyldiimidazole, *N,N'*-


dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbo-
 diimide (or hydrochloride thereof), *N,N*-disuccinimidyl carbonate,
 benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro-
 phosphate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexa-
 5 fluorophosphate, benzotriazol-1-yloxytris-pyrrolidinophosphonium
 hexafluorophosphate, bromo-tris-pyrrolidinophosphonium hexafluoro-
 phosphate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetra-
 fluorocarbonate) or 1-cyclohexylcarbodiimide-3-propyloxymethyl
 polystyrene, a suitable base (e.g. as mentioned in process step (i) above) and
 10 an appropriate solvent (e.g. as mentioned in process step (i) above).
 Alternatively an azodicarboxylate may be employed under Mitsunobo
 conditions known to those skilled in the art;

(iii) for compounds of formula I in which X represents a direct bond and Y
 15 represents a $-C(O)-$ or a $-C(S)-$ group, reaction of a compound of formula II
 as hereinbefore defined with a compound of formula V,



wherein Y^a represents either $-C(O)-$ (so forming a ketene) or $-C(S)-$ (so
 forming a thioketene) and R^3 is as hereinbefore defined, under conditions
 20 known to those skilled in the art;

(iv) for compounds of formula I, in which X represents $-NH-$ and Y
 represents $-C(O)-$ or $-C(S)-$, reaction of a compound of formula II as
 hereinbefore defined with a compound of formula VI,



25 wherein R^3 and Y^a are as hereinbefore defined (so forming an isocyanate or
 an isothiocyanate, as appropriate), under conditions known to those skilled
 in the art. For example, for compounds of formula VI in which Y is
 $-C(O)-$, reaction may be performed in a suitable solvent (e.g. toluene) at

elevated temperature (e.g. 100°C). For compounds of formula VI in which Y is -C(S)-, reaction may be performed in a suitable solvent (e.g. acetone) in the presence of a suitable base (e.g. potassium carbonate) at room temperature;


5

(v) for compounds of formula I in which Y represents -C(O)- or -C(S)-, reaction of a compound of formula II with:

(a) a compound of formula VII,



10 (b) a compound of formula VIII,



wherein, in both cases, Y^a is as hereinbefore defined; or

(c) when Y represents -C(O)-, triphosgene, followed by:

15 (1) for compounds of formula I in which X represents a direct bond, reaction with a organometallic reagent of formula IX,



wherein M represents a metal such as Mn, Fe, Ni, Cu, Zn, Pd or Ce, or a salt or complex thereof and R³ is as hereinbefore defined;

20 (2) for compounds of formula I wherein X represents O, reaction with an alcohol of formula X,



wherein R³ is as hereinbefore defined; or

(3) for compounds of formula I wherein X represents -N(R⁴)-, reaction with
25 an amine of formula XI,



wherein R³ and R⁴ are as hereinbefore defined,

in all cases under reaction condition that are known to those skilled in the art;


- (vi) for compounds of formula I in which X represents $-N(R^4)-$, and R^4 is other than hydrogen, reaction of a corresponding compound of formula I in which X represents $-N(H)-$ with a compound of formula XII,



wherein R^4 and L^1 are as hereinbefore defined under standard reaction conditions;

- (vii) for compounds of formula I in which Y represents $-C(S)-$, reaction of a corresponding compound of formula I in which Y represents $-C(O)-$ with a suitable reagent for the conversion of a carbonyl group to a thiocarbonyl group, such as P_2S_5 or Lawesson's reagent, under conditions known to the person skilled in the art;

(viii) reaction of a compound of formula XIII,



XIII


wherein R^3 , Y and X are as hereinbefore defined, with a compound of formula XIV,



wherein R^1 and R^2 are as hereinbefore defined under coupling conditions, for example as described in process step (ii) above. Alternatively,

compounds of formula XIII may first be activated by treatment with a suitable reagent (e.g. oxalyl chloride, thionyl chloride, etc) in an appropriate solvent (e.g. dichloromethane, dimethylformamide, THF or benzene), resulting in the formation of the respective acyl chloride. This activated intermediate may then be reacted with a compound of formula XIV under standard conditions, such as those described hereinbefore in process step (i) above; or

(ix) reaction of a compound of formula XV,



wherein R^2 , R^3 , Y and X are as hereinbefore defined, with a compound of formula XVI,



wherein L^2 represents a suitable leaving group, such as halo (e.g. chloro, bromo and iodo), $-OSO_2CF_3$, $-B(OH)_2$, $-Sn(R^2)_3$ (wherein R^2 is preferably methyl or butyl) or $-Bi(R^1)_2$, and R^1 is as hereinbefore defined, for example in the presence of a catalyst containing, preferably, Pd or Cu, and a base.

Compounds of formula II and protected derivatives thereof may be prepared by reaction of a compound of formula XIV as hereinbefore defined with either:

(I) dipyrazolo[1,5-*a*;1',5'-*d'*]pyrazine-4,9-dione, for example under standard conditions, for example as described hereinbefore in process step (i); or

(II) 1*H*-pyrazole-3-carboxylic acid, an N-protected, and/or an O-activated derivative, thereof, for example under conditions such as those described hereinbefore in process step (viii) above.

5 Compounds of formula XIII may be prepared by reaction of 1*H*-pyrazole-3-carboxylic acid, or an O-protected derivative thereof, with an appropriate reagent under similar conditions to those described in respect any of process steps (i) to (vii) above.

10 Compounds of formula XV may be prepared by reaction of a compound of formula XVII,



wherein R^2 is as hereinbefore defined with a compound of formula XIII as hereinbefore defined, for example under conditions such as those described
15 hereinbefore in respect of process step (viii) above.

Dipyrzolo[1,5- α ;1',5'- d']pyrazine-4,9-dione may be prepared from 1*H*-pyrazole-3-carboxylic acid under dimerising conditions, for example in the presence of thionyl chloride (optionally in the presence of DMF) at reflux.
20 Other dimerising reagents include carbodiimides, such as 1,3-dicyclohexylcarbodiimide.

1*H*-Pyrazole-3-carboxylic acid and protected derivatives thereof may be prepared from 3-methyl-1(2)*H*-pyrazole, for example as described
25 hereinafter.

Compounds of formulae III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIV, XVI and XVII are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or

by conventional synthetic procedures, in accordance with standard techniques, from available starting materials using appropriate reagents and reaction conditions.

5 The substituents R^1 , R^2 and R^3 as hereinbefore defined may be modified one or more times, after or during the processes described above for preparation of compounds of formula I by way of methods that are well known to those skilled in the art. Examples of such methods include substitutions, reductions, oxidations, alkylations, hydrolyses, esterifications, and
10 etherifications. The precursor groups can be changed to a different such group, or to the groups defined in formula I, at any time during the reaction sequence.

Compounds of the formula I may be isolated from their reaction mixtures
15 using conventional techniques.

It will be appreciated by those skilled in the art that, in the processes described above and hereinafter, the functional groups of intermediate compounds may need to be protected by protecting groups.

20

The protection and deprotection of functional groups may take place before or after a reaction in the above-mentioned schemes.

Protecting groups may be removed in accordance with techniques that are
25 well known to those skilled in the art and as described hereinafter. For example, protected compounds/intermediates described herein may be converted chemically to unprotected compounds using standard deprotection techniques.

The type of chemistry involved will dictate the need, and type, of protecting groups as well as the sequence for accomplishing the synthesis.

The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J W F McOmie, Plenum Press (1973), and
5 "Protective Groups in Organic Synthesis", 3rd edition, T.W. Greene & P.G.M. Wutz, Wiley-Interscience (1999).

Medical and Pharmaceutical Uses

10

Compounds of formula I and salts thereof are useful because they possess pharmacological activity. Such compounds are therefore indicated as pharmaceuticals.

15 To the applicant's knowledge, compounds of formula I have not been disclosed before for use as pharmaceuticals. According to a further aspect of the invention there is provided a compound of the invention, as hereinbefore defined but without the provisos, for use as a pharmaceutical.

20 Although compounds of formula I and salts thereof may possess pharmacological activity as such, certain pharmaceutically-acceptable (e.g. "protected") derivatives of compounds of formula I may exist or be prepared which may not possess such activity, but may be administered parenterally or orally and thereafter be metabolised in the body to form
25 compounds of formula I. Such compounds (which may possess some pharmacological activity, provided that such activity is appreciably lower than that of the "active" compounds to which they are metabolised), may therefore be described as "prodrugs" of compounds of formula I. All

prodrugs of compounds of formula I are included within the scope of the invention.

By "prodrug of a compound of formula I", we include compounds that form
5 a compound of formula I, in an experimentally-detectable amount, within a predetermined time (e.g. about 1 hour), following oral or parenteral administration.

Compounds of formula I and salts thereof are useful because, in particular,
10 they may inhibit the activity of lipoxxygenases (and particularly 15-lipoxygenase), i.e. they prevent the action of 15-lipoxygenase or a complex of which the 15-lipoxygenase enzyme forms a part and/or may elicit a 15-lipoxygenase modulating effect, for example as may be demonstrated in the test described below. Compounds of formula I may thus be useful in the
15 treatment of those conditions in which inhibition of a lipoxxygenase, and particularly 15-lipoxygenase, is required.

Compounds of formula I, and pharmaceutically acceptable salts thereof, are thus expected to be useful in the treatment of inflammation.

20

The term "inflammation" will be understood by those skilled in the art to include any condition characterised by a localised or a systemic protective response, which may be elicited by physical trauma, infection, chronic diseases, such as those mentioned hereinbefore, and/or chemical and/or
25 physiological reactions to external stimuli (e.g. as part of an allergic response). Any such response, which may serve to destroy, dilute or sequester both the injurious agent and the injured tissue, may be manifest by, for example, heat, swelling, pain, redness, dilation of blood vessels and/or increased blood flow, invasion of the affected area by white blood

cells, loss of function and/or any other symptoms known to be associated with inflammatory conditions.

The term "inflammation" will thus also be understood to include any inflammatory disease, disorder or condition *per se*, any condition that has an inflammatory component associated with it, and/or any condition characterised by inflammation as a symptom, including *inter alia* acute, chronic, ulcerative, specific, allergic and necrotic inflammation, and other forms of inflammation known to those skilled in the art. The term thus also includes, for the purposes of this invention, inflammatory pain and/or fever.

Accordingly, compounds of formula I may be useful in the treatment of asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, allergic disorders, rhinitis, inflammatory bowel disease, ulcers, inflammatory pain, fever, atherosclerosis, coronary artery disease, vasculitis, pancreatitis, arthritis, osteoarthritis, rheumatoid arthritis, conjunctivitis, iritis, scleritis, uveitis, wound healing, dermatitis, eczema, psoriasis, stroke, diabetes, autoimmune diseases, Alzheimer's disease, multiple sclerosis, sarcoidosis, Hodgkin's disease and other malignancies, and any other disease with an inflammatory component.

Compounds of formula I and pharmaceutically acceptable salts thereof may also have effects that are not linked to inflammatory mechanisms, such as in the reduction of bone loss in a subject. Conditions that may be mentioned in this regard include osteoporosis, osteoarthritis, Paget's disease and/or periodontal diseases. Compounds of formula I and pharmaceutically acceptable salts thereof may thus also be useful in increasing bone mineral density, as well as the reduction in incidence and/or healing of fractures, in subjects.

Compounds of formula I are indicated both in the therapeutic and/or prophylactic treatment of the above-mentioned conditions.

5 According to a further aspect of the present invention, there is provided a method of treatment of a disease which is associated with, and/or which can be modulated by inhibition of, a lipoxygenase (such as 15-lipoxygenase), and/or a method of treatment of a disease in which inhibition of the activity of a lipoxygenase, and particularly 15-lipoxygenase, is desired and/or
10 required (e.g. inflammation), which method comprises administration of a therapeutically effective amount of a compound of the invention, as hereinbefore defined but without the provisos, to a patient suffering from, or susceptible to, such a condition.

15 "Patients" include mammalian (including human) patients.

The term "effective amount" refers to an amount of a compound, which confers a therapeutic effect on the treated patient. The effect may be objective (i.e. measurable by some test or marker) or subjective (i.e. the
20 subject gives an indication of or feels an effect).

Compounds of formula I will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, by any other parenteral route or *via* inhalation, in a
25 pharmaceutically acceptable dosage form.

Compounds of formula I may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal

administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.

Such formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

Compounds of formula I may also be combined with other therapeutic agents that are useful in the treatment of inflammation as defined herein (e.g. NSAIDs, coxibs, corticosteroids, analgesics, inhibitors of 5-lipoxygenase, inhibitors of FLAP (5-lipoxygenase activating protein), and leukotriene receptor antagonists (LTRas), and/or other therapeutic agents that are useful in the treatment of inflammation).

According to a further aspect of the invention, there is provided a combination product comprising:

(A) a compound of the invention, as hereinbefore defined but without the provisos; and

(B) another therapeutic agent that is useful in the treatment of inflammation,

wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

Such combination products provide for the administration of compound of formula I or salt thereof in conjunction with the other therapeutic agent, and

may thus be presented either as separate formulations, wherein at least one of those formulations comprises compound of formula I/salt, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single
5 formulation including compound of formula I/salt and the other therapeutic agent).

Thus, there is further provided:

- 10 (1) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos, another therapeutic agent that is useful in the treatment of inflammation, and a pharmaceutically-acceptable adjuvant, diluent or carrier; and
- 15 (2) a kit of parts comprising components:
 - (a) a pharmaceutical formulation including a compound of the invention, as hereinbefore defined but without the provisos, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and
 - (b) a pharmaceutical formulation including another therapeutic agent
20 that is useful in the treatment of inflammation in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
- 25 Compounds of formula I and salts thereof may be administered at varying doses. Oral dosages may range from between about 0.01 mg/kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably about 0.01 to about 10 mg/kg/day, and more preferably about 0.1 to about 5.0 mg/kg/day. For oral administration, the compositions typically contain

between about 0.01 mg to about 500 mg, and preferably between about 1 mg to about 100 mg, of the active ingredient. Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during constant rate infusion. Advantageously, compounds may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.

In any event, the physician, or the skilled person, will be able to determine the actual dosage which will be most suitable for an individual patient, which is likely to vary with the route of administration, the type and severity of the condition that is to be treated, as well as the species, age, weight, sex, renal function, hepatic function and response of the particular patient to be treated. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Compounds of formula I and salts thereof may have the advantage that they are effective and/or selective inhibitors of lipoxygenases, and particularly 15-lipoxygenase.

Compounds of formula I and salts thereof may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the stated indications or otherwise.

Biological Test

The assay employed takes advantage of the ability of lipid hydroperoxides to oxidize the non-fluorescent diphenyl-1-pyrenylphosphine (DPPP) to its
5 corresponding fluorescent phosphine oxide. Fluorescence is measured using a dual-scanning microplate spectrofluorometer, Spectramax Gemini, from Molecular Devices. DPPP was purchased from Molecular Probes. Linoleic acid was from Biomol and PBS (phosphate buffered saline) from
10 Gibco Life Technologies. The assay is performed in 96-well plates at room temperature (20-22°C). The following are added (in the following order) to each well:

- a) 35 μ l of Dulbecco's phosphate buffered saline (PBS);
- b) inhibitor (i.e. compound) or vehicle (0.5 μ l DMSO);
- c) 10 μ L of a 5 x concentrated 15-lipoxygenase solution in PBS. The plates
15 are incubated for 5 minutes at room temperature;
- d) 5 μ l of 2 mM linoleic acid in PBS. The plate is then incubated for 20 minutes at room temperature;
- e) the enzymatic reaction is terminated by the addition of 50 μ l methanol; and
- 20 f) 50 μ l of 200 μ M DPPP in methanol is added to each well.

After 30 minutes at room temperature, the fluorescence can be read using an excitation wavelength of 358 nm and an emission wavelength of 379 nm.

Examples

25 The invention is illustrated by way of the following examples, in which the following abbreviations may be employed:

DMF	dimethylformamide
DMSO	dimethylsulfoxide

EtOAc	ethyl acetate
MS	mass spectrum
NMR	nuclear magnetic resonance
THF	tetrahydrofuran

Starting materials and chemical reagents specified in the syntheses described below are commercially available from, *e.g.* Sigma-Aldrich Fine Chemicals.

Example 1

1-Benzoyl-1*H*-pyrazole-3-carboxylic acid pyridin-3-ylamide

(a) 1*H*-Pyrazole-3-carboxylic acid

An aqueous solution of KMnO₄ (40.9 g, 0.26 mol) was added to a stirred solution of 3-methyl-1(2)*H*-pyrazole (9.8 ml, 0.12 mol) in 0.5 L water. The mixture was heated at reflux for 5 h. The black suspension was cooled, filtered and the filtrate concentrated to a small volume. The solution was acidified with 3 N HCl and the white solid that formed was collected and washed with Et₂O to give the sub-title compound in 100 % yield.

¹H NMR (DMSO-*d*₆, 200 MHz) δ 7.75 (d, *J* = 1.5 Hz, 1H) and 6.75 (d, *J* = 1.5 Hz, 1H).

(b) 1*H*-Pyrazole-3-carbonyl chloride

Thionyl chloride (20 mL) was added to a solution of 1*H*-pyrazole-3-carboxylic acid (5.0 g, 44.6 mmol; see step (a) above) in THF (40 mL) at room temperature. The mixture was heated at reflux for 1 h, and concentrated to dryness to afford the sub-title compound. The solid was used without further purification.

(c) 1*H*-Pyrazole-3-carboxylic acid pyridin-2-ylamide.

NaH (60 % dispersion in mineral oil, 1.34 g, 33.5 mmol) was added to a solution of pyridin-2-ylamine (3.0 g, 31.9 mmol) in THF (150 mL). The solution was stirred at room temperature for 1 hour and freshly prepared
5 pyrazole-3-carbonyl chloride (4.66 g, 35.7 mmol; see step (b) above) was added. The mixture was stirred for 1 h and 10 mL water was added. The mixture was concentrated to a small volume and extracted twice with EtOAc. The combined extracts were washed with H₂O, dried with Na₂SO₄ and concentrated to dryness to afford the sub-title compound.

10 ¹H NMR (CDCl₃, 200 MHz) δ 10.07 (s, 1H), 8.49 (d, *J* = 8 Hz, 1H), 8.38 (d, *J* = 6 Hz, 1H), 7.83 (dd, *J* = 6 Hz, *J* = 8 Hz, 1H), 7.68 (d, *J* = 2.5 Hz, 1H), 7.14 (dd, *J* = 6 Hz, *J* = 8 Hz, 1H), 7.02 (d, *J* = 2.5 Hz, 1H)

(d) 1-Benzoyl-1*H*-pyrazole-3-carboxylic acid pyridin-3-ylamide.

15 A solution of 1*H*-pyrazole-3-carboxylic acid pyridin-2-ylamide (100 mg, 0.53 mmol; see step (c) above) in anhydrous THF (2mL) was added to NaH (60% dispersion in mineral oil, 22 mg, 0.56 mmol) with stirring at room temperature. After 1 h, benzoyl chloride (65μL, 0.56 mmol) was added and the mixture was stirred for an additional hour. Water (1 mL) was added and
20 the mixture was concentrated to dryness. EtOAc (2 mL) and Na₂CO₃ (0.2 M, 1 mL) were added and the phases were separated. The organic layer was washed with NaCl (aq. sat.), passed through a short column of silica gel and concentrated to dryness. The residue was triturated with Et₂O to afford the title compound (40 mg) as a white solid.

25 MS (M⁺+H) *m/z* 293.

Example 2

1-(2,5-Dimethyl-3-furoyl)-1H-pyrazole-3-carboxylic acid pyridin-3-ylamide

The title compound was prepared as described in Example 1(d) from
5 1H-pyrazole-3-carboxylic acid pyridin-2-ylamide (see Example 1(c)) and
2,5-dimethyl-3-furoyl chloride.

MS ($M^+ + H$) m/z 311.

Example 3

10 1-(1-Methyl-1H-pyrrol-2-yl)-1H-pyrazole-3-carboxylic acid pyridin-3-ylamide

The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid pyridin-2-ylamide (see Example 1(c)) and 1-
methyl-2-pyrrolyl chloride.

15 MS ($M^+ + H$) m/z 296.

Example 4

1-(3-Methyl-2-thienoyl)-1H-pyrazole-3-carboxylic acid pyridin-3-ylamide

The title compound was prepared as described in Example 1(d) from
20 1H-pyrazole-3-carboxylic acid pyridin-2-ylamide (see Example 1(c)) and 3-
methyl-2-thienoyl chloride.

MS ($M^+ + H$) m/z 313.

Example 5

25 1-(4-Pentylbenzoyl)-1H-pyrazole-3-carboxylic acid pyridin-3-ylamide

The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid pyridin-2-ylamide (see Example 1(c)) and 4-
pentylbenzoyl chloride.

MS ($M^+ + H$) m/z 363.

Example 62-{[1-(2-Ethoxybenzoyl)-1*H*-pyrazole-3-carbonyl]amino}thiophene-3-carboxylic acid methyl ester

5

(a) Dipyrazolo[1,5-*a*:1',5'-*d*]pyrazine-4,9-dione

A mixture of pyrazole-3-carboxylic acid (44.0 g, 0.39 mol; see Example 1(a) above), DMF (0.5 mL), and thionyl chloride (150 mL) was heated at reflux for 3 days. The solvents were evaporated and the residue dried under
10 high-vacuum, to give the sub-title compound which was used without further purification.

(b) 2-[(1*H*-Pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester

15 NaH (60% dispersion in mineral oil, 0.61 g, 15.4 mmol) was added to a solution of dipyrazolo[1,5-*a*:1',5'-*d*]pyrazine-4,9-dione (2.4 g, 12.7 mmol; see step (a) above) and 2-aminothiophene-3-carboxylic acid methyl ester (2.0 g, 12.7 mmol) in THF (100 mL) at room temperature. The mixture was stirred for 1 h and 10 mL water was added. The mixture was concentrated to
20 a small volume and extracted twice with EtOAc. The combined extracts were washed with H₂O, dried with Na₂SO₄ and concentrated to dryness providing the sub-title compound.

¹H NMR (DMSO-*d*₆, 200 MHz) δ 8.0 (d, *J* = 2 Hz, 1H), 7.21 (d, *J* = 5.8 Hz, 1H), 7.06 (d, *J* = 5.8 Hz, 1H), 6.87 (d, *J* = 2 Hz, 1H) and 3.86 (s, 3H).

25

(c) 2-{[1-(2-Ethoxybenzoyl)-1*H*-pyrazole-3-carbonyl]amino}thiophene-3-carboxylic acid methyl ester

The title compound was prepared as described in Example 1(d) from 2-[(1*H*-pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester (see step (b) above) and 2-ethoxybenzoyl chloride.

MS ($M^+ + H$) m/z 400.

Example 7

2-{[1-(3-Trifluoromethylbenzoyl)-1*H*-pyrazole-3-carbonyl]amino}-thiophene-3-carboxylic acid methyl ester

The title compound was prepared as described in Example 1(d) from 2-[(1*H*-pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester (see Example 6(b)) and 3-trifluorobenzoyl chloride.

MS ($M^+ + H$) m/z 424.

Example 8

2-{[1-(5-Fluoro-2-methylbenzoyl)-1*H*-pyrazole-3-carbonyl]amino}-thiophene-3-carboxylic acid methyl ester

The title compound was prepared as described in Example 1(d) from 2-[(1*H*-pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester (see Example 6(b)) and 5-fluoro-2-methylbenzoyl chloride.

MS ($M^+ + H$) m/z 388.

Example 9

2-{[1-(3-Methyl-2-thienoyl)-1*H*-pyrazole-3-carbonyl]amino}thiophene-3-carboxylic acid methyl ester

The title compound was prepared as described in Example 1(d) from 2-[(1*H*-pyrazole-3-carbonyl)amino]thiophene-3-carboxylic acid methyl ester (see Example 6(b)) and 3-methyl-2-thienoyl chloride.

MS ($M^+ + H$) m/z 376.

Example 10

1-(2,5-Dimethyl-3-furoyl)-1*H*-pyrazole-3-carboxylic acid (1,3,5-trimethyl-
5 1*H*-pyrazol-4-yl)amide

(a) 1*H*-Pyrazole-3-carboxylic acid (1,3,5-trimethyl-1*H*-pyrazol-4-yl)amide

The title compound was prepared as described in Example 6(b) from
dipyrzolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione (see Example 6(a)) and 1,3,5-
10 trimethyl-1*H*-pyrazol-4-ylamine.

¹H NMR (DMSO-*d*₆, 200 MHz) δ 11.7 (m, 1H), 9.27 (m, 1H), 7.86 (m, 1H),
3.64 (s, 3H), 2.04 (s, 3H) and 1.95 (s, 3H).

(b) 1-(2,5-Dimethyl-3-furoyl)-1*H*-pyrazole-3-carboxylic acid (1,3,5-tri-
15 methyl-1*H*-pyrazol-4-yl)amide

The title compound was prepared as described in Example 1(d) from
1*H*-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1*H*-pyrazol-4-yl)amide (see
step (a) above) and 2,5-dimethyl-3-furoyl chloride.

MS ($M^+ + H$) m/z 342.

20

Example 11

1-(1-Methyl-1*H*-pyrrol-2-yl)-1*H*-pyrazole-3-carboxylic acid (1,3,5-tri-
methyl-1*H*-pyrazol-4-yl)amide

The title compound was prepared as described in Example 1(d) from
25 1*H*-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1*H*-pyrazol-4-yl)amide (see
Example 10(a)) and 1-methyl-2-pyrrolyl chloride.

MS ($M^+ + H$) m/z 327.

Example 12

1-(3-Methyl-2-benzofuroyl)-1H-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide

The title compound was prepared as described in Example 1(d) from
5 1H-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide (see
Example 10(a)) and 3-methyl-2-benzofuroyl chloride.

MS ($M^+ + H$) m/z 378.

Example 13

10 1-(2-Fluoro-5-iodobenzoyl)-1H-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide

The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid (1,3,5-trimethyl-1H-pyrazol-4-yl)amide (see
Example 10(a)) and 2-fluoro-5-iodobenzoyl chloride.

15 MS ($M^+ + H$) m/z 468.

Example 14

1-(2-Ethoxybenzoyl)-1H-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

20

(a) 1H-Pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

The title compound was prepared as described in Example 6(b) from
dipyrazolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione (see Example 6(a)) and 3-
methylisoxazol-5-ylamine.

25 1H NMR (DMSO- d_6 , 200 MHz) δ 7.85 (d, $J = 2$ Hz, 1H), 6.86 (d, $J = 2$ Hz, 1H), 6.24 (s, 1H), 2.2 (s, 3H).

(b) 1-(2-Ethoxybenzoyl)-1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

The title compound was prepared as described in Example 1(d) from 1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide (see step (a) above) and 2-ethoxybenzoyl chloride.

MS ($M^+ + H$) m/z 341.

Example 15

10 1-(3-Methyl-2-benzofuroyl)-1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

The title compound was prepared as described in Example 1(d) from 1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide (see Example 14(a)) and 3-methyl-2-benzofuroyl chloride.

MS ($M^+ + H$) m/z 351.

Example 16

1-(2-Furoyl)-1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

The title compound was prepared as described in Example 1(d) from 1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide (see Example 14(a)) and 2-furoyl chloride.

MS ($M^+ + H$) m/z 287.

Example 17

25 1-(1-Naphthoyl)-1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide

The title compound was prepared as described in Example 1(d) from 1*H*-pyrazole-3-carboxylic acid (3-methylisoxazol-5-yl)amide (see Example 14(a)) and 1-naphthoyl chloride.

MS ($M^+ + H$) m/z 347.

Example 18

4-[[1-(2,5-Dimethyl-3-furoyl)-1H-pyrazole-3-carbonyl]amino]benzoic acid methyl ester

5 (a) 4-[(1H-Pyrazole-3-carbonyl)amino]benzoic acid methyl ester.

Freshly prepared pyrazole-3-carbonyl chloride (5.80 g, 44.6 mmol; see Example 1(b)) was added to a solution of 4-aminobenzoic acid methyl ester (2.7 g, 17.9 mmol) in pyridine (50 mL). The solution was stirred at 85 °C for 3 h and concentrated. The residue was extracted twice with EtOAc and
10 the combined extracts were washed with H₂O, dried with Na₂SO₄ and concentrated to dryness. The solid was washed with Et₂O to give the sub-title compound.

¹H NMR (CDCl₃, 200 MHz) δ 9.0 (s, 1H), 8.1 (d, *J* = 6 Hz, 2 H), 7.8 (d, *J* = 6 Hz, 2 H), 7.7 (s, *J* = 2 Hz, 1H), 7.05 (s, *J* = 2 Hz, 1H), 3.93 (s, 3H).

15

(b) 4-[[1-(2,5-Dimethyl-3-furoyl)-1H-pyrazole-3-carbonyl]amino]benzoic acid methyl ester

The title compound was prepared as described in Example 1(d) from 4-[(1H-pyrazole-3-carbonyl)amino]benzoic acid methyl ester (see step (a)
20 above) and 2,5-dimethyl-3-furoyl chloride.

MS (M⁺+H) *m/z* 368.

Example 19

4-[[1-(5-Fluoro-2-methylbenzoyl)-1H-pyrazole-3-carbonyl]amino]benzoic acid methyl ester

25

The title compound was prepared as described in Example 1(d) from 4-[(1H-pyrazole-3-carbonyl)amino]benzoic acid methyl ester (see Example 18(a)) and 5-fluoro-2-methylbenzoyl chloride.

MS (M⁺+H) *m/z* 382.

Example 20

4- {[1-(4-Pentylbenzoyl)-1*H*-pyrazole-3-carbonyl]amino}benzoic acid methyl ester

5 The title compound was prepared as described in Example 1(d) from 4-[(1*H*-pyrazole-3-carbonyl)amino]benzoic acid methyl ester (see Example 18(a)) and 4-pentylbenzoyl chloride.

MS ($M^+ + H$) m/z 420.

10 Example 21

4- {[1-(2-Furoyl)-1*H*-pyrazole-3-carbonyl]amino}benzoic acid methyl ester

The title compound was prepared as described in Example 1(d) from 4-[(1*H*-pyrazole-3-carbonyl)amino]benzoic acid methyl ester (see Example 18(a)) and 2-furoyl chloride.

15 MS ($M^+ + H$) m/z 340.

Example 22

1-(1-Methyl-1*H*-pyrrol-2-yl)-1*H*-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide

20

(a) 1*H*-Pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide

Dipyrzolo[1,5-*a*;1',5'-*d'*]pyrazine-4,9-dione (1.0 g, 5.3 mmol; see Example 6(a)) was added to a solution of dimethylaminophenylamine dihydrochloride (2.0 g ; 11.6 mmol) and Et₃N (3.2 mL, 23.2 mmol) in DMF
25 (20 mL). The mixture was stirred at 85°C for 1 h and then concentrated. The residue was extracted twice with EtOAc and the combined extracts were washed with H₂O, dried with Na₂SO₄ and concentrated to dryness. The residue was purified by chromatography to afford the sub-title compound.

^1H NMR (CDCl_3 , 200 MHz) δ 8.55 (s, 1H), 7.6 (d, $J = 2.5$ Hz, 1 H), 7.52 (d, $J = 9$ Hz, 2 H), 6.91 (d, $J = 2.5$ Hz, 1H), 6.74 (s, $J = 9$ Hz, 2H), 2.92 (s, 6 H)

5 (b) 1-(1-Methyl-1H-pyrrol-2-yl)-1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide

The title compound was prepared as described in Example 1(d) from 1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide (see step (a) above) and 1-methyl-2-pyrrolyl chloride.

10 MS ($\text{M}^+ + \text{H}$) m/z 338.

Example 23

1-(4-Pentylbenzoyl)-1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide

15 The title compound was prepared as described in Example 1(d) from 1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide (see Example 22(a)) and 4-pentylbenzoyl chloride.

MS ($\text{M}^+ + \text{H}$) m/z 405.

20 Example 24

1-(3-Methyl-2-thienoyl)-1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide

The title compound was prepared as described in Example 1(d) from 1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide (see

25 Example 22(a)) and 3-methyl-2-thienoyl chloride.

MS ($\text{M}^+ + \text{H}$) m/z 355.

Example 251-(1-Naphthoyl)-1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)-amide

The title compound was prepared as described in Example 1(d) from
5 1H-pyrazole-3-carboxylic acid (4-dimethylaminophenyl)amide (see
Example 22(a)) and 1-naphthoyl chloride.

MS ($M^+ + H$) m/z 385.

Example 26

10 1-(2-Ethoxybenzoyl)-1H-pyrazole-3-carboxylic acid (5-chloro-2-cyano-phenyl)amide

(a) 1H-Pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide.

The title compound was prepared as described in Example 6(b) from
15 dipyrazolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione (see Example 6(a)) and 5-
chloro-2-cyanoaniline.

1H NMR ($CDCl_3$, 200 MHz) δ 10.3 (s, 1H), 8.03 (m, 1 H), 7.98 (m, 1 H),
7.93 (d, $J=8$ Hz, 1H), 7.48 (2, $J=8$ Hz, 1H), 6.86 (m, 1 H).

20 (b) 1-(2-Ethoxybenzoyl)-1H-pyrazole-3-carboxylic acid (5-chloro-2-cyano-phenyl)amide

The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide (see step (a)
above) and 2-ethoxybenzoyl chloride.

25 MS ($M^+ + H$) m/z 395.

Example 27

1-(5-Fluoro-2-methylbenzoyl)-1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide

The title compound was prepared as described in Example 1(d) from
5 1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide (see
Example 26(a)) and 5-fluoro-2-methylbenzoyl chloride.

MS ($M^+ + H$) m/z 383.

Example 28

10 1-(2-Furoyl)-1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)-
amide

The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide (see
Example 26(a)) and 2-furoyl chloride.

15 MS ($M^+ + H$) m/z 341.

Example 29

1-(1-Naphthoyl)-1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)-
amide

20 The title compound was prepared as described in Example 1(d) from
1H-pyrazole-3-carboxylic acid (5-chloro-2-cyanophenyl)amide (see
Example 26(a)) and 1-naphthoyl chloride.

MS ($M^+ + H$) m/z 401.

Example 301-Oleoyl-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide(a) 1H-Pyrazole-3-carboxylic acid (2-chlorophenyl)amide

- 5 A mixture of dipyrazolo[1,5- α ;1',5'- d]pyrazine-4,9-dione (1.88 g, 10 mmol; see Example 6(a)), 2-chloroaniline (6.38 g, 50 mmol) and 4-(*N,N*-dimethylamino)pyridine (1.22 g, 10 mmol) was stirred at 120°C for 30 min. After cooling to room temperature, EtOH (20 mL), followed by water (100 mL) and isohexane (100 mL) was added. The mixture was shaken for 10 min. The solid was filtered off, washed with 50% aqueous EtOH (20 mL), water (50 mL) and isohexane (50 mL), and dried in vacuum, to give the sub-title compound (yield: 2.45 g, 55%).

(b) 1-Oleoyl-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide

- 15 A mixture of 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (55 mg, 0.25 mmol; see step (a) above), oleoyl chloride (146 mg, 0.30 mmol) and 4-(*N,N*-dimethylamino)pyridine (36 mg, 0.30 mmol) in CH₂Cl₂ (5 mL) was stirred at 40°C for 2 days. The mixture was diluted with CH₂Cl₂ (10 mL), washed with water (2×10 mL) and concentrated. Chromatographic purification gave the title compound (yield: 83 mg, 68%).

20 MS ($M^+ + H$) m/z 486.

- ¹H NMR (CDCl₃, 400 MHz) δ 9.41 (s, 1H), 8.56 (dd, $J = 8$ Hz, 1 Hz, 1H), 8.30 (d, $J = 3$ Hz, 1H), 7.42 (dd, $J = 8$ Hz, 1 Hz, 1H), 7.33 (td, $J = 8$ Hz, 1 Hz, 1H), 7.08 (td, $J = 8$ Hz, 1 Hz, 1H), 7.03 (d, $J = 3$ Hz, 1H), 5.36 (ddd, $J = 11$ Hz, 6 Hz, 3 Hz, 1H), 5.32 ddd, $J = 11$ Hz, 6 Hz, 3 Hz, 1H), 3.17 (t, $J = 8$ Hz, 2H), 1.96-2.08 (m, 4H), 1.78-1.88 (m, 2H), 1.18-1.50 (m, 20H), 0.86 (t, $J = 7$ Hz, 3H).

^{13}C NMR (CDCl_3 , 100.5 MHz) δ 172.03, 158.7, 150.2, 134.4, 130.3, 130.2, 129.8, 129.2, 128.0, 124.9, 123.0, 121.3, 109.5, 33.92, 32.0, 29.85, 29.77, 29.6, 29.4 (2C), 29.31, 29.25, 29.18, 27.3, 27.2, 24.6, 22.8, 14.2.

5 Example 31

3-(2-Chlorophenylcarbamoyl)-1*H*-pyrazole-1-carboxylic acid (1*R*,2*S*,5*R*)-(-)-menthol ester

A mixture of 1*H*-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (56 mg, 0.25 mmol; see Example 30(a)), (-)-menthyl chloroformate (82 mg, 0.38 mmol), and 4-(*N,N*-dimethylamino)pyridine (45 mg, 375 μmol) in dichloromethane (5 mL) was stirred at 40°C for 16 h. The mixture was concentrated, dissolved in EtOAc, washed with water, and dried with MgSO_4 . Chromatographic purification afforded the title product (yield: 69 mg, 69%).

15 MS ($\text{M}^+ + \text{H}$) m/z = 404.

^1H NMR (CDCl_3 , 400 MHz) δ 9.42 (s, 1H), 8.49 (dd, J = 9, 2 Hz, 1H), 8.18 (d, J = 3 Hz, 1H), 7.41 (dd, J = 9, 2 Hz, 1H), 7.31 (dt, J = 9, 2 Hz, 1H), 7.07 (dt, J = 9, 2 Hz, 1H), 7.01 (d, J = 3 Hz, 1H), 4.92 (dt, J = 12, 4 Hz, 1H), 2.25 (m, 1H), 2.01 (dsept, J = 8, 3 Hz, 1H), 1.80-1.70 (m, 2H), 1.70-1.50 (m, 2H), 1.29-1.08 (m, 2H), 0.95 (dd, J = 7, 2 Hz, 7H), 0.84 (d, J = 7 Hz, 3H).

^{13}C NMR (100.5 MHz) δ 158.7, 150.5, 148.3, 134.3, 132.6, 129.2, 127.7, 124.8, 123.4, 121.5, 109.1, 80.5, 47.0, 40.4, 33.9, 31.4, 26.7, 23.8, 21.9, 20.5, 16.7.

Example 323-(2-Chlorophenylcarbamoyl)-1H-pyrazole-1-carboxylic acid 2-chlorobenzyl ester

The title compound was prepared as described in Example 31 from
5 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and 2-chlorobenzyl chloroformate.

MS ($M^+ + H$) m/z 390.

1H NMR ($CDCl_3$, 400 MHz) δ 9.44 (s, 1H), 8.49 (dd, $J = 8$ Hz, 1 Hz, 1H),
8.21 (d, $J = 3$ Hz, 1H), 7.59 (dd, $J = 7$ Hz, 1H), 7.39-7.47 (m, 2H), 7.28-
10 7.38 (m, 3H), 7.07 (td, $J = 8$ Hz, 1 Hz, 1H), 7.02 (d, $J = 3$ Hz, 1H), 5.62 (s,
2H).

^{13}C NMR (100.5 MHz) δ 151.0, 148.5, 134.3, 134.0, 133.1, 131.9, 130.5,
130.4, 130.0, 129.3, 127.8, 127.2, 125.0, 123.5, 121.6, 109.5.

15 Example 333-(2-Chlorophenylcarbamoyl)-1H-pyrazole-1-carboxylic acid 4-chlorophenyl ester

The title compound was prepared as described in Example 31 from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
20 and 4-chlorophenyl chloroformate.

MS ($M^+ + H$) m/z 376.

Example 3425 1H-Pyrazole-1,3-dicarboxylic acid 3-[(2-chlorophenyl)amide] 1-dimethylamide

The title compound was prepared as described in Example 30(b) from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and *N,N*-dimethylcarbamoyl chloride.

MS ($M^+ + H$) m/z 293.

Example 351H-Pyrazole-1,3-dicarboxylic acid 1-[(3-chlorophenyl)amide] 3-[(2-chlorophenyl)amide]

5 A mixture of 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (55 mg, 0.25 mmol; see Example 30(a)), 3-chlorophenylisocyanate (46 mg, 0.30 mmol) and toluene (5 mL) was stirred at 100°C for 18 h. The solution was concentrated and isohexane (10 mL) was added. The title compound was filtered off and washed with isohexane (10 mL) (yield: 65 mg, 69%).

10 MS ($M^+ + H$) m/z 375.

1H NMR (C_6D_6 , 400 MHz) δ 9.05 (s, 1H), 8.91 (d, $J = 8$ Hz, 1H), 8.31 (s, 1H), 7.72 (d, $J = 3$ Hz, 1H), 7.61 (s, 1H), 7.07 (d, $J = 8$ Hz, 1H), 6.94 (t, $J = 8$ Hz, 1H), 6.85 (d, $J = 8$ Hz, 1H), 6.72 (t, $J = 8$ Hz, 1H), 6.69 (d, $J = 3$ Hz, 1H), 6.58 (t, $J = 8$ Hz, 1H).

15 ^{13}C NMR (100.5 MHz) δ 158.1, 149.1, 145.3, 137.5, 135.0, 134.7, 130.6, 130.1, 129.0, 128.4, 124.9, 124.7, 122.5, 121.3, 119.6, 117.5, 109.4.

Example 361H-Pyrazole-1,3-dicarboxylic acid 3-[(2-chlorophenyl)amide] 1-[(3-fluorophenyl)amide]

20 The title compound was prepared as described in Example 35 from 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a)) and 3-fluorophenylisocyanate.

MS ($M^+ + H$) m/z 359.

Example 37

1H-Pyrazole-1,3-dicarboxylic acid 3-[(2-chlorophenyl)amide] 1-[(3-tri-fluoromethylphenyl)amide]

The title compound was prepared as described in Example 35 from
5 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and 3-trifluoromethylphenylisocyanate.

MS ($M^+ + H$) m/z 409.

Example 38

10 1H-Pyrazole-1,3-dicarboxylic acid 3-[(2-chlorophenyl)amide] 1-[(4-nitro-phenyl)amide]

The title compound was prepared as described in Example 35 from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and 4-nitrophenylisocyanate.

15 MS ($M^+ + H$) m/z 386.

Example 39

1-(Octane-1-sulfonyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)-amide

20 The title compound was prepared as described in Example 30(b) from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and 1-octanesulfonyl chloride.

MS ($M^+ + H$) m/z 398.

Example 401-(3-Chlorobenzenesulfonyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide

The title compound was prepared as described in Example 30(b) from 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a)) and 3-chlorobenzenesulfonyl chloride.

MS ($M^+ + H$) m/z 396.

1H NMR ($CDCl_3$, 400 MHz) δ 9.25 (s, 1H), 8.45 (dd, $J = 8$ Hz, 1 Hz, 1H), 8.17 (d, $J = 3$ Hz, 1H), 8.09 (t, $J = 2$ Hz, 1H), 7.97 (dt, $J = 8$ Hz, 1 Hz, 1H), 7.68 (ddd, $J = 8$ Hz, 2 Hz, 1 Hz, 1H), 7.54 (t, $J = 8$ Hz, 1H), 7.41 (dd, $J = 8$ Hz, 1 Hz, 1H), 7.29 (td, $J = 8$ Hz, 1 Hz, 1H), 7.07 (td, $J = 8$ Hz, 1 Hz, 1H), 7.00 (d, $J = 3$ Hz, 1H).

^{13}C NMR (100.5 MHz) δ 152.0, 137.8, 136.0, 135.5, 134.1, 133.1, 131.0, 129.3, 128.7, 127.9, 126.6, 125.1, 123.3, 121.4, 121.3, 109.2.

Example 411-(4-tert-Butylbenzenesulfonyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide

The title compound was prepared as described in Example 30(b) from 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a)) and 4-tert-butylbenzenesulfonyl chloride.

MS ($M^+ + H$) m/z 418.

1H NMR ($CDCl_3$, 400 MHz) δ 9.27 (s, 1H), 8.45 (dd, $J = 8$ Hz, 1 Hz, 1H), 8.16 (d, $J = 3$ Hz, 1H), 7.98-8.02 (m, 2H), 7.56-7.61 (m, 2H), 7.40 (dd, $J = 8$ Hz, 1 Hz, 1H), 7.29 (td, $J = 8$ Hz, 1 Hz, 1H), 7.07 (td, $J = 8$ Hz, 1 Hz, 1H), 6.96 (d, $J = 3$ Hz, 1H), 1.33 (s, 9H).

^{13}C NMR (100.5 MHz) δ 159.6, 158.3, 151.3, 134.3, 133.1, 132.9, 129.3, 128.6 (2C), 127.9, 126.8 (2C), 125.0, 123.2, 121.4, 108.8, 35.6, 31.0 (3C).

Example 42

5-[3-(2-Chlorophenylcarbamoyl)-1H-pyrazole-1-sulfonyl]furan-2-carboxylic acid methyl ester

The title compound was prepared as described in Example 30(b) from
5 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (see Example 30(a))
and 5-carbomethoxy-2-furansulfonyl chloride.

MS ($M^+ + H$) m/z 410.

Example 43

10 1-(3-Chlorobenzoyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)-methanamide

(a) 1H-Pyrazole-3-carboxylic acid (2-chlorophenyl)methanamide.

The title compound was prepared as described in Example 30(a) from
15 dipyrazolo[1,5- α ;1',5'- d]pyrazine-4,9-dione (see Example 6(a)) and 2-chloro-*N*-methylaniline.

MS ($M^+ + H$) m/z 236.

(b) 1-(3-Chlorobenzoyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)-methanamide
20

The title compound was prepared as described in Example 30(b) from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methanamide (see step (a)
above) and 3-chlorobenzoyl chloride.

MS ($M^+ + H$) m/z 374.

25

Example 44

1H-Pyrazole-1,3-dicarboxylic acid 1-[(3-chlorophenyl)amide] 3-[(2-chlorophenyl)methylamide]

The title compound was prepared as described in Example 35 from
5 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide (see Example 43(a)) and 3-chlorophenylisocyanate.

MS ($M^+ + H$) m/z 389.

Example 45

10 3-[(2-Chlorophenyl)methylcarbamoyl]-1H-pyrazole-1-carboxylic acid 2-chlorobenzyl ester

The title compound was prepared as described in Example 31 from
1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide (see Example 43(a)) and 2-chlorobenzyl chloroformate.

15 MS ($M^+ + H$) m/z 404.

Example 46

1-(3-Chlorobenzenesulfonyl)-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide

20 The title compound was prepared as described in Example 30(b) from 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide (see Example 43(a)) and 3-chlorobenzenesulfonyl chloride.

MS ($M^+ + H$) m/z 410.

25 Example 47

1-Phenylthiocarbamoyl-1H-pyrazole-3-carboxylic acid (2-chlorophenyl)-amide

A mixture of 1H-pyrazole-3-carboxylic acid (2-chlorophenyl)amide (10 mg, 44.5 μ mol; see Example 43(a)), phenylisothiocyanate (30 mg, 0.22 mmol)

and anhydrous K_2CO_3 (69 mg, 0.5 mmol) in dry acetone (2 mL) was stirred for 5 h at room temperature. The reaction mixture was then filtered and concentrated. Purification by chromatography gave the title compound (yield: 12 mg, 76%) as a white solid.

5 MS ($M^+ + H$) m/z 357.

1H NMR (400 MHz) δ 10.52 (s, 1H), 9.22 (s, 1H), 8.84 (d, $J = 3$ Hz, 1H), 8.55 (dd, $J = 9, 2$ Hz, 1H), 7.80 (m [app d, $J = 8$ Hz], 2H), 7.50 (m [app t, $J = 8$ Hz], 2H), 7.43 (dd, $J = 9, 2$ Hz, 1H), 7.35 (m [app dq, $J = 7, 1$ Hz], 2H), 7.11 (dt, $J = 8, 1$ Hz, 1H), 7.06 (d, $J = 3$ Hz, 1H).

10 ^{13}C NMR (100.5 MHz) δ 172.0, 158.3, 148.7, 136.7, 134.1, 133.2, 129.23, 129.16, 128.0, 127.4, 125.0, 123.6, 122.9, 121.4, 110.0.

Example 48

15 *N*-(2-Chloro-4-fluorophenyl)-1-(1-methylpiperazine-4-carbonyl)-1*H*-pyrazole-3-carboxamide

(a) *N*-(2-Chloro-4-fluorophenyl)-1*H*-pyrazole-3-carboxamide

The sub-title compound was prepared according to the procedure described above in Example 30(a) using dipyrazolo[1,5- α :1',5'- d']pyrazine-4,9-dione
20 (see Example 6(a)) and 2-chloro-4-fluoroaniline.

MS (M^+) $m/z = 239$.

1H NMR (DMSO- D_6 , 300 MHz) δ 13.48 (broad s, 1H), 9.67 (s, 1H), 7.99 (m, 1H), 7.91 (d, 1H), 7.56 (dd, 1H), 7.28 (ddd, 1H), 6.81 (d, 1H).

25 (b) *N*-(2-Chloro-4-fluorophenyl)-1-(1-methylpiperazine-4-carbonyl)-1*H*-pyrazole-3-carboxamide

N-(2-Chloro-4-fluorophenyl)-1*H*-pyrazole-3-carboxamide (50 mg, 209 μ mol, 1 equiv.; see step (a) above) was mixed with the hydrochloride salt of 4-methyl-piperazine-1-carbonyl chloride (83 mg, 410 μ mol, 2 equiv.) and

DMAP (50 mg, 410 μ mol, 2 equiv.) in toluene (5 mL) at 90°C. The reaction mixture was left stirring for 16 h and then cooled. The precipitate from the reaction mixture was collected and recrystallised from EtOH/EtOAc to yield the hydrochloride salt of the title compound (a white powder). 0.5 M NaOH (aq.) and ethyl acetate were added to the salt. The organic phase was dried and concentrated to afford the free base of the title compound as an off-white solid.

MS: $m/z = 366 (M^+ + 1)$.

^1H NMR (CDCl_3): δ 9.21 (br s, 1H), 8.56 (m, 1H), 8.17 (d, $J = 3$ Hz, 1H), 7.18 (m, 1H), 7.07 (m, 1H), 6.98 (d, $J = 3$ Hz, 1H), 3.99 (m, 4H), 2.68 (m, 4H), 2.44 (s, 3H).

Example 49

N^3 -(2-Chlorophenyl)- N^1 -(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-1H-pyrazole-1,3-dicarboxamide

1H-Pyrazole-3-carboxylic acid (2-chlorophenyl)amide (50 mg, 226 μ mol, 1 equiv.; see Example 30(a)), 2,2,2-trifluoro-1-(4-isocyanatopiperidin-1-yl)ethanone (76 mg, 338 μ mol, 1.5 equiv.) and DMAP (33mg, 270 μ mol, 1.2 equiv.) were added to toluene at room temperature. The reaction was left stirring for 24 h, after which the excess solvent removed. Purification by chromatography afforded the title compound.

MS: $m/z = 444 (M^+ + 1)$.

^1H NMR ($\text{dmso}-d_6$): δ 9.86 (s, 1H), 8.52 (d, $J = 8$ Hz, 1H), 8.45 (d, $J = 3$ Hz, 1H), 7.76 (dd, $J = 8, 1$ Hz, 1H), 7.60 (dd, $J = 8, 1$ Hz, 1H), 7.42 (dt, $J = 8, 1$ Hz, 1H), 7.31 (dt, $J = 8$ Hz, 1H); 6.99 (d, $J = 3$ Hz, 1H), 4.31 (m, 1H), 4.12-4.02 (m, 1H), 3.91 (m, 1H), 3.43 (t, $J = 12$ Hz, 1H), 3.08 (t, $J = 12$ Hz, 1H), 2.09-1.99 (m, 2H), 1.71-1.56 (m, 2H).

Example 50Pyrazole-1,3-dicarboxylic acid-1-[(3-chlorophenyl)amide]-3-(methylphenylamide)5 (a) 1H-Pyrazole-3-carboxylic acid methylphenylamide

A mixture of dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (1.00 g, 5.30 mmol; see Example 6(a)), *N*-methyl aniline (5.00 g, 0.38 mmol), and 4-(*N,N*-dimethylamino)pyridine (0.650 g, 5.30 mmol) was stirred at 120°C for 4 h. After cooling to room temperature, EtOH (15 ml), water (50 ml) and
10 *iso*-hexane (50 ml) were added. The resulting mixture was shaken and then the aqueous phase was separated. The organic phase was concentrated to afford the crude product (1.27 g). Purification by recrystallisation from EtOH afforded the sub-title compound (yield: 0.990 g, 47%)

MS ($M^+ + H$) m/z = 202.

15 1H NMR (DMSO- D_6 , 400 MHz) δ 7.60 (s, 1H), 7.55-7.10 (m, 5H), 6.15 (s, 1H), 3.35 (s, 3H).

(b) Pyrazole-1,3-dicarboxylic acid-1-[(3-chlorophenyl)amide]-3-(methylphenylamide)

20 A mixture of 1H-pyrazole-3-carboxylic acid methylphenylamide (0.200 g, 0.994 mmol; see step (a) above), 1-chloro-3-isocyanatobenzene (0.183 g, 1.19 mmol) and toluene (5 ml) was stirred at 100°C for 18 h. The reaction mixture was then cooled to room temperature and the solvent was evaporated. *iso*-Hexane (10 ml) was then added and the resulting
25 precipitate was filtered off. The precipitate was then washed with *iso*-hexane (20 ml) and then dried under reduced pressure to give the title compound (yield: 0.212 g, 60 %).

MS ($M^+ + H$) m/z = 356.

^1H NMR (CDCl_3 , 400 MHz) δ 8.45 (s, 1H), 8.05 (s, 1H), 7.60-7.00 (m, 9H), 6.35 (s, 1H), 3.50 (s, 3H).

Example 51

5 1-(4-*tert*-Butylbenzenesulfonyl)-1*H*-pyrazole-3-carboxylic acid methylphenylamide

A mixture of 1*H*-pyrazole-3-carboxylic acid methylphenylamide (0.200 g, 0.994 mmol; see Example 50(a)), 4-*tert*-butylbenzenesulfonyl chloride (0.278 g, 1.19 mmol), 4-(*N,N*-dimethylamino)pyridine (0.146 g, 1.19 mmol) and dichloromethane (5 ml) was stirred at 40°C for 48 h. The reaction mixture was then cooled to room temperature, dichloromethane (10 ml) was added and the mixture was washed twice with water (10 ml). The organic phase was filtered through a short silica plug (eluting with acetone) and concentrated. The crude product was purified by recrystallisation from
15 hexane to afford the title compound (yield: 0.257 g, 65%).
MS ($\text{M}^+\text{+H}$) m/z = 399.

^1H NMR (CDCl_3 , 400 MHz) δ 7.87 (s, 1H), 7.73-7.58 (m, 2H), 7.53-7.41 (m, 2H), 7.25-6.95 (m, 5), 6.38 (s, 1H), 3.40 (s, 3H), 1.29 (s, 9H).

^{13}C NMR (CDCl_3 , 100.5 MHz) δ 162.4, 158.7, 151.8, 144.0, 133.5, 131.0,
20 129.1, 128.2, 127.3, 126.5, 110.0, 38.4, 35.5, 31.0.

Example 52

1-(3-Chlorobenzenesulfonyl)-1*H*-pyrazole-3-carboxylic acid methylphenylamide

25 A mixture of 1*H*-pyrazole-3-carboxylic acid methylphenylamide (0.100 g, 0.497 mmol; see Example 50(a)), 3-chlorobenzenesulfonyl chloride (0.126 g, 0.596 mmol), 4-(*N,N*-dimethylamino)pyridine (0.073 g, 0.596 mmol) and dichloromethane (5 ml) was stirred at 40°C for 48 h. The reaction mixture was then cooled to room temperature, dichloromethane (20 ml) was added

and the mixture was washed twice with water (10 ml). The organic phase was filtered through a short silica plug (eluting with acetone) and concentrated. The crude product was purified by recrystallisation from *iso*-hexane to afford the title compound (yield: 0.140 g, 75%) as white crystals.

5 MS ($M^+ + H$) m/z = 376.

1H NMR ($CDCl_3$, 400 MHz) δ 7.92 (s, 1H), 7.74 (s, 1H), 7.67-7.50 (m, 2H), 7.48-7.34 (m, 1H), 7.33-6.92 (m, 5H), 6.50 (s, 1H), 3.50 (s, 3H).

^{13}C NMR ($CDCl_3$, 100.5 MHz) δ 162.0, 152.4, 143.9, 138.1, 135.5, 134.9, 131.2, 130.7, 129.1, 128.3, 127.5, 127.2, 126.5, 110.5, 38.4.

10

Example 53

1-(3-Chlorobenzoyl)-1H-pyrazole-3-carboxylic acid methylphenylamide

A mixture of 1H-pyrazole-3-carboxylic acid methylphenylamide (0.100 g, 0.497 mmol; see Example 50(a)), 3-chlorobenzoyl chloride (0.104 g, 0.596 mmol), 4-(*N,N*-dimethylamino)pyridine (0.073 g, 0.596 mmol) and dichloromethane (5 ml) was stirred at 40°C for 48 h. The reaction mixture was then cooled to room temperature, dichloromethane (10 ml) was added and the mixture was washed twice with water (10 ml). The organic phase was filtered through a short silica plug (eluting with acetone) and concentrated. The crude product was purified by recrystallisation from *iso*-hexane, benzene and diethyl ether to afford the title compound (yield: 0.025 g, 15%) as white crystals.

15
20

MS ($M^+ + H$) m/z = 340.

1H NMR ($CDCl_3$, 400 MHz) δ 8.26 (s, 1H), 7.84 (s, 1H), 7.58-7.10 (m, 8H), 6.65 (s, 1H), 3.50 (s, 3H).

25

Example 543-(Methylphenylcarbamoyl)pyrazole-1-carboxylic acid 2-chlorobenzyl ester

A mixture of 1*H*-pyrazole-3-carboxylic acid methylphenylamide (0.100 g, 0.497 mmol; see Example 50(a)), 2-chlorobenzyl chloroformate (0.122 g, 0.596 mmol), 4-(*N,N*-dimethylamino)pyridine (0.073 g, 0.596 mmol) and dichloromethane (5 ml) was stirred at 40°C for 48 h. The reaction mixture was then cooled to room temperature, dichloromethane (10 ml) was added and the mixture was washed twice with water (10 ml). The organic phase was separated and concentrated. The crude product was then purified by recrystallisation from *iso*-hexane, then from MeOH and finally from benzene to afford the title compound (yield: 0.050 g, 27%) as white crystals.

MS ($M^+ + H$) m/z = 370.

1H NMR ($CDCl_3$, 400 MHz) δ 7.90 (s, 1H), 7.55-7.05 (m, 9H), 6.20 (s, 1H), 5.48 (s, 2H), 3.50 (s, 3H).

Anal. calcd for $C_{19}H_{16}ClN_3O_3$: C, 61.71; H, 4.36; Found: C, 61.29; H, 4.66.

Example 55Pyrazole-1,3-dicarboxylic acid 1-butylamide 3-[(2-chlorophenyl)methylamide]

A mixture of 1*H*-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide (0.052 g, 0.220 mmol; see Example 43(a)), 1-isocyanatobutane (0.026 g, 0.265 mmol), and toluene (5 ml) was stirred at 100°C for 20 h. The reaction mixture was then cooled to room temperature. The solvent was then evaporated, diethyl ether (30 ml) was added and the resulting precipitate was filtered off. The mother liquor was evaporated to afford the title compound (yield: 0.054 g, 73%) as a thick oil.

MS ($M^+ + H$) m/z = 335.

Example 56Pyrazole-1,3-dicarboxylic acid 1-benzylamide 3-[(2-chlorophenyl)methylamide]

A mixture of 1*H*-pyrazole-3-carboxylic acid (2-chlorophenyl)methylamide
5 (0.052 g, 0.220 mmol; see Example 43(a)), isocyanatomethylbenzene
(0.036 g, 0.270 mmol), and toluene (5 ml) was stirred at 100°C for 24 h.
The reaction mixture was then cooled to room temperature, filtered,
concentrated and then dried under high vacuum for three days to give the
pure title compound (yield: 0.048 g, 58%).

10 MS ($M^+ + H$) m/z = 369.

1H NMR ($CDCl_3$, 400 MHz) δ 7.98 (m, 1H), 7.48-7.10 (m, 7H), 7.08-7.0
(m, 1H), 6.91-6.83 (m, 1H), 6.61-6.55 (m, 1H), 6.45 (br s, 1H), 4.50-4.30
(m, 2H), 3.35 (s, 3H);

^{13}C NMR ($CDCl_3$, 100.5 MHz) δ 161.9, 149.0, 148.4, 142.0, 136.9, 133.2,
15 130.1, 130.0, 129.2, 128.9, 128.6, 128.5, 128.2, 127.5, 110.4, 44.5, 37.1.

Example 57Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(2-chloro-
pyridin-3-yl)amide

20

(a) 1*H*-Pyrazole-3-carboxylic acid (2-chloropyridin-3-yl)amide

A mixture of dipyrazolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione (2.66 mmol, 500
mg, see Example 6(a)), 3-amino-2-chloropyridine (6.64 mmol, 854 mg),
and DMAP (1.33 mmol, 162 mg) was heated at 190°C for 5 minutes using
25 microwaves with a Smith synthesizer from Personal Chemistry. The
reaction mixture was allowed to cool and mixed with water (10 mL) and
EtOAc (10 mL). The organic layer was separated and the aqueous layer
was extracted with ethyl acetate (3×5 mL). The combined organic phases

were concentrated and purified by preparative HPLC to give 139 mg of the sub-title compound as a white solid.

MS (M^+) m/z = 222.

1H NMR (DMSO- D_6 , 300 MHz) δ 13.63 (broad s, 1H), 9.60 (broad s, 1H),
5 8.48 (d, 1H), 8.22 (dd, 1H), 7.95 (d, 1H), 7.50 (dd, 1H), 6.83 (d, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(2-chloro-pyridin-3-yl)amide

A mixture of 1H-pyrazole-3-carboxylic acid (2-chloropyridin-3-yl)amide
10 (0.25 mmol, 55 mg; see step (a) above), 3,4-methylenedioxyphenyl isocyanate (0.30 mmol, 49 mg) and toluene (0.5 mL) was heated at 180°C for 10 min using microwaves with a Smith synthesizer from Personal Chemistry. The title compound was precipitated by addition of isohexane (4 mL) and collected by filtration (yield 34 mg).

15 MS (M^+) m/z = 385.

1H NMR ($CDCl_3$, 300 MHz) δ 9.22 (s, 1H), 8.92 (dd, 1H), 8.79 (s, 1H),
8.43 (d, 1H), 8.20 (dd, 1H), 7.37 (dd, 1H), 7.31 (d, 1H), 7.10 (d, 1H), 6.95
(dd, 1H), 6.86 (d, 1H), 6.04 (s, 2H).

20 Example 58

6-{[3-(2-Chloropyridin-3-yl)carbamoyl]pyrazole-1-carbonyl}-amino}hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid (2-chloropyridin-3-yl)amide (see Example 57(a)) and ethyl 6-isocyanatohexanoate.

25 MS (M^+) m/z = 407.

¹H NMR (CDCl₃, 300 MHz) δ 9.19 (s, 1H), 8.88 (dd, 1H), 8.33 (d, 1H), 8.18 (dd, 1H), 7.35 (ddd, 1H), 7.10 (t, 1H), 7.02 (d, 1H), 4.12 (q, 2H), 3.52 (q, 2H), 2.35 (t, 2H), 1.80-1.66 (m, 4H), 1.54-1.42 (m, 2H), 1.25 (t, 3H).

5 Example 59

Pyrazole-1,3-dicarboxylic acid 3-(2-chloropyridin-3-yl)amide 1-pentyl-
amide

The title compound was prepared according to the procedure described
above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid (2-
10 chloropyridin-3-yl)amide (see Example 57(a)) and pentyl isocyanate.

MS (M⁺) *m/z* = 335.

¹H NMR (CDCl₃, 300 MHz) δ 9.17 (s, 1H), 8.89 (dd, 1H), 8.32 (d, 1H),
8.17 (dd, 1H), 7.33 (dd, 1H), 7.05 (t, 1H), 7.01 (d, 1H), 3.50 (q, 2H), 1.76-
1.64 (m, 2H), 1.46-1.37 (m, 4H), 0.99-0.90 (m, 3H).

15

Example 60

Pyrazole-1,3-dicarboxylic acid 1-benzo[1,3]dioxol-5-ylamide 3-(2-fluoro-5-
trifluoromethylphenylamide)

20 (a) 1*H*-Pyrazole-3-carboxylic acid 2-fluoro-5-trifluoromethylphenylamide

The sub- title compound was prepared according to the procedure described
above in Example 57(a) using dipyrazolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione
(see Example 6(a)) and 2-fluoro-5-(trifluoromethyl)aniline.

MS (M⁺) *m/z* = 273.

25 ¹H NMR (DMSO-D₆, 300 MHz) δ 12.94 (broad s, 1H), 9.45 (broad s, 1H),
8.26 (dd, 1H), 7.91 (d, 1H), 7.62 (dd, 1H), 7.55 (dd, 1H), 6.83 (d, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 1-benzo[1,3]dioxol-5-ylamide 3-(2-fluoro-5-trifluoromethylphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-fluoro-5-trifluoromethylphenylamide (see step (a) above) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M^+) m/z = 436.

^1H NMR (DMSO- D_6 , 300 MHz) δ 10.43 (broad s, 1H), 10.17 (broad s, 1H), 8.55 (d, 1H), 8.29 (dd, 1H), 7.70 (ddd, 1H), 7.60 (dd, 1H), 7.31 (d, 1H), 7.12 (dd, 1H), 7.06 (d, 1H), 6.98 (d, 1H), 6.06 (s, 2H).

Example 61

Pyrazole-1,3-dicarboxylic acid 3-(2-fluoro-5-trifluoromethylphenylamide) 1-(3-trifluoromethylphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-fluoro-5-trifluoromethylphenylamide (see Example 60(a)) and 3-trifluoromethylphenyl isocyanate.

MS (M^+) m/z = 460.

^1H NMR (CDCl_3 , 400 MHz) δ 9.00 (s, 1H), 8.90-8.86 (m, 2H), 8.44 (d, 1H), 7.96 (dd, 1H), 7.88 (dd, 1H), 7.59 (dd, 1H), 7.51 (ddd, 1H), 7.43 (dddd, 1H), 7.30 (ddd, 1H), 7.13 (d, 1H).

Example 62Pyrazole-1,3-dicarboxylic acid 3-(3-cyanophenylamide) 1-(4-trifluoromethoxyphenylamide)5 (a) 1H-Pyrazole-3-carboxylic acid 3-cyanophenylamide

The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 3-cyanoaniline.

MS (M^+) m/z = 212.

10 1H NMR (DMSO- D_6 , 300 MHz) δ 13.53 (s, 1H), 10.45 (s, 1H), 8.28 (s, 1H), 8.10 (dd, 1H), 7.90 (s, 1H), 7.50-7.60 (m, 2H), 6.80 (s, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 3-(3-cyanophenylamide) 1-(4-trifluoromethoxyphenylamide)

15 The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid 3-cyanophenylamide (see step (a) above) and 4-(trifluoromethoxy)phenyl isocyanate.

MS (M^+) m/z = 415.

20 1H NMR ($CDCl_3$, 300 MHz) δ 9.00 (s, 1H), 8.75 (s, 1H), 8.43 (s, 1H), 8.10-8.03 (m, 2H), 7.77-7.70 (m, 2H), 7.53 (dd, 1H), 7.46 (ddd, 1H), 7.35-7.29 (m, 2H), 7.12 (d, 1H).

Example 63

Pyrazole-1,3-dicarboxylic acid 3-(2-chloro-4-fluorophenylamide) 1-(4-trifluoromethoxyphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-chloro-4-fluorophenylamide (see Example 48(a)) and 4-(trifluoromethoxy)phenyl isocyanate.

MS (M^+) m/z = 442.

1H NMR ($CDCl_3$, 300 MHz) δ 9.07 (s, 1H), 8.95 (s, 1H), 8.60-8.34 (m, 2H), 7.70-7.60 (m, 2H), 7.40-7.18 (m, 3H), 7.17-7.00 (m, 2H).

Example 64

Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(2-chloro-4-fluorophenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-chloro-4-fluorophenylamide (see Example 48(a)) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M^+) m/z = 402.

1H NMR ($CDCl_3$, 300 MHz) δ 9.09 (s, 1H), 8.79 (s, 1H), 8.52 (dd, 1H), 8.41 (d, 1H), 7.30 (d, 1H), 7.23 (dd, 1H), 7.09 (ddd, 1H), 7.08 (d, 1H), 6.95 (dd, 1H), 6.86 (d, 1H), 6.04 (s, 2H).

Example 65

6-{[3-(2-Chloro-4-fluorophenylcarbamoyl)pyrazole-1-carbonyl]-amino}-hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-chloro-4-fluorophenylamide (see Example 48(a)) and ethyl 6-isocyanatohexanoate.

MS (M^+) m/z = 424.

^1H NMR (CDCl_3 , 300 MHz) δ 9.06 (s, 1H), 8.48 (dd, 1H), 8.32 (d, 1H), 7.21 (dd, 1H), 7.10 (t, 1H), 7.08 (ddd, 1H), 7.02 (d, 1H), 4.12 (q, 2H), 3.51 (q, 2H), 2.35 (t, 2H), 1.79-1.65 (m, 4H), 1.53-1.41 (m, 2H), 1.25 (t, 3H).

5

Example 66

Pyrazole-1,3-dicarboxylic acid 3-(2-chloro-4-fluorophenylamide) 1-pentylamide

The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid 2-chloro-4-fluorophenylamide (see Example 48 (a)) and pentyl isocyanate.

MS (M^+) m/z = 352.

^1H NMR (CDCl_3 , 300 MHz) δ 9.08 (s, 1H), 8.51 (dd, 1H), 8.32 (d, 1H), 7.21 (dd, 1H), 7.13-7.00 (m, 1H), 3.50 (q, 2H), 1.78-1.65 (m, 2H), 1.47-1.38 (m, 4H), 1.00-0.92 (m, 3H).

Example 67

Pyrazole-1,3-dicarboxylic acid 3-(2,6-dichlorophenylamide) 1-(4-trifluoromethoxyphenylamide)

20

(a) 1H-Pyrazole-3-carboxylic acid 2,6-dichlorophenylamide

The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 2,6-dichloroaniline.

MS (M^+) m/z = 255.

^1H NMR ($\text{DMSO}-D_6$, 300 MHz) δ 13.45 (broad s, 1H), 10.03 (broad s, 1H), 7.87 (s, 1H), 7.56 (d, 2H), 7.37 (t, 1H), 6.77 (s, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 3-(2,6-dichlorophenylamide) 1-(4-trifluoromethoxyphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2,6-dichlorophenylamide (see step (a) above) and 4-(trifluoromethoxy)phenyl isocyanate.

MS (M^+) m/z = 458.

1H NMR ($CDCl_3$, 300 MHz) δ 9.01 (s, 1H), 8.41 (d, 1H), 8.36 (s, 1H), 7.74-7.68 (m, 2H), 7.47-7.42 (m, 2H), 7.33-7.26 (m, 3H), 7.12 (d, 1H).

Example 68

Pyrazole-1,3-dicarboxylic acid 3-(2-bromo-4-trifluoromethoxyphenylamide) 1-(3-trifluoromethylphenylamide)

(a) 1*H*-Pyrazole-3-carboxylic acid 2-bromo-4-trifluoromethoxyphenylamide

The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 2-bromo-4-trifluoromethoxyaniline.

MS (M^+) m/z = 349.

1H NMR ($DMSO-D_6$, 300 MHz) δ 13.63 (broad s, 1H), 9.70 (broad s, 1H), 8.21 (d, 1H), 7.93 (d, 1H), 7.82 (dd, 1H), 7.49 (ddd, 1H), 6.83 (d, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 3-(2-bromo-4-trifluoromethoxyphenylamide) 1-(3-trifluoromethylphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-bromo-4-trifluoromethoxyphenylamide (see step (a) above) and 3-trifluoromethylphenyl isocyanate.

MS (M^+) m/z = 536.

¹H NMR (DMSO-D₆, 300 MHz) δ 13.57 (s, 1H), 9.70 (s, 1H), 8.21 (d, 1H), 7.95 (d, 1H), 7.83 (dd, 1H), 7.54-7.47 (m, 1H), 7.20 (t, 1H), 6.86-6.73 (m, 3H).

5 Example 69

Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(2-bromo-4-trifluoromethoxyphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-bromo-4-trifluoromethoxyphenylamide (see Example 68(a)) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M⁺) *m/z* = 512.

¹H NMR (CDCl₃, 300 MHz) δ 9.24 (s, 1H), 8.81 (s, 1H), 8.62 (d, 1H), 8.42 (d, 1H), 7.54 (dq, 1H), 7.34-7.29 (m, 2H), 7.09 (d, 1H), 6.94 (dd, 1H), 6.86 (d, 1H), 6.04 (s, 2H).

Example 70

Pyrazole-1,3-dicarboxylic acid 3-(2-bromo-4-trifluoromethoxyphenylamide) 1-pentylamide

20 The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-bromo-4-trifluoromethoxyphenylamide (see Example 68(a)) and pentyl isocyanate.

MS (M⁺) *m/z* = 462.

¹H NMR (CDCl₃, 300 MHz) δ 9.22 (s, 1H), 8.61 (d, 1H), 8.33 (d, 1H), 7.52 (d, 1H), 7.29 (dd, 1H), 7.05 (t, 1H), 7.03 (t, 1H), 3.51 (q, 2H), 1.78-1.65 (m, 2H), 1.47-1.37 (m, 4H), 1.00-0.93 (m, 3H).

Example 71

6-{{[3-(2-Bromo-4-trifluoromethoxyphenylcarbamoyl)pyrazole-1-carbonyl]-
amino}hexanoic acid ethyl ester

The title compound was prepared according to the procedure described
above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 2-bromo-4-
trifluoromethoxyphenylamide (see Example 68(a)) and ethyl 6-
isocyanatohexanoate.

MS (M^+) m/z = 534.

^1H NMR (CDCl_3 , 300 MHz) δ 9.20 (s, 1H), 8.58 (d, 1H), 8.33 (d, 1H), 7.52
(dq, 1H), 7.29 (dd, 1H), 7.09 (t, 1H), 7.03 (d, 1H), 4.12 (q, 2H), 3.52 (q,
2H), 2.36 (t, 2H), 1.79-1.66 (m, 4H), 1.54-1.42 (m, 2H), 1.26 (t, 3H).

Example 72

6-{{[3-(3-Methylpyridin-2-ylcarbamoyl)pyrazole-1-carbonyl]amino}-
hexanoic acid ethyl ester

(a) 1*H*-Pyrazole-3-carboxylic acid (3-methylpyridin-2-yl)amide

The sub- title compound was prepared according to the procedure described
above in Example 57(a) using dipyrazolo[1,5-*a*;1',5'-*d*]pyrazine-4,9-dione
(see Example 6(a)) and 2-amino-3-methylpyridine.

MS (M^+) m/z = 202.

^1H NMR ($\text{DMSO}-d_6$, 300 MHz) δ 13.44 (s, 1H), 10.09 (s, 1H), 8.29 (dd,
1H), 7.84 (s, 1H), 7.71 (dd, 1H), 7.24 (dd, 1H), 6.84 (s, 1H), 2.21 (s, 3H).

(b) 6-{{[3-(3-Methylpyridin-2-ylcarbamoyl)pyrazole-1-carbonyl]amino}hex-
anoic acid ethyl ester

The title compound was prepared according to the procedure described
above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid (3-

methylpyridin-2-yl)amide (see step (a) above) and ethyl 6-isocyanatohexanoate.

MS (M^+) m/z = 387.

1H NMR (DMSO- D_6 , 300 MHz) δ 10.30 (s, 1H), 8.69 (t, 1H), 8.39 (d, 1H), 8.33 (dd, 1H), 7.77 (dd, 1H), 7.30 (dd, 1H), 6.97 (d, 1H), 4.02 (q, 2H), 3.30 (dt, 2H), 2.29 (t, 2H), 2.23 (s, 3H), 1.64-1.50 (m, 4H), 1.40-1.27 (m, 2H), 1.15 (t, 3H).

Example 73

10 Pyrazole-1,3-dicarboxylic acid 3-(3-methylpyridin-2-yl)amide 1-pentylamide

The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid (3-methylpyridin-2-yl)amide (see Example 72(a)) and pentyl isocyanate.

15 MS (M^+) m/z = 315.

1H NMR ($CDCl_3$, 300 MHz) δ 9.07 (s, 1H), 8.30 (d, 1H), 8.28 (d, 1H), 7.65 (d, 1H), 7.18 (dd, 1H), 7.12 (t, 1H), 6.98 (d, 1H), 3.44 (q, 2H), 2.38 (s, 3H), 1.71-1.59 (m, 2H), 1.43-1.33 (m, 4H), 0.97-0.89 (m, 3H).

20 Example 74

6-{[3-(2-Methoxy-6-methylphenylcarbamoyl)pyrazole-1-carbonyl]amino}-hexanoic acid ethyl ester

(a) 1H-Pyrazole-3-carboxylic acid 2-methoxy-6-methylphenylamide

25 The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 2-methoxy-6-methylaniline.

MS (M^+) m/z = 231.

¹H NMR (DMSO-D₆, 300 MHz) δ 13.35 (s, 1H), 9.15 (s, 1H), 7.83 (s, 1H), 7.17 (dd, 1H), 6.89 (d, 1H), 6.85 (d, 1H), 6.75 (s, 1H), 3.73 (s, 3H), 2.15 (s, 3H).

5 (b) 6-[[3-(2-Methoxy-6-methylphenylcarbamoyl)pyrazole-1-carbonyl]-amino]hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid 2-methoxy-6-methylphenylamide (see step (a) above) and ethyl 6-isocyanatohexanoate.

10 MS (M⁺) m/z = 416.

¹H NMR (CDCl₃, 300 MHz) δ 8.29 (d, 1H), 8.26 (s, 1H), 7.28 (s, 1H), 7.26-7.16 (m, 1H), 7.00 (d, 1H), 6.91 (d, 1H), 6.81 (d, 1H), 4.08 (q, 2H), 3.84 (s, 3H), 3.50 (q, 2H), 2.35 (t, 2H), 2.32 (s, 3H), 1.78-1.64 (m, 4H), 1.54-1.41 (m, 2H), 1.22 (t, 3H).

15

Example 75

Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(4-trifluoromethylphenylamide)

20 (a) 1H-Pyrazole-3-carboxylic acid 4-trifluoromethylphenylamide

The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 4-trifluoromethylaniline.

MS (M⁺) m/z = 255.

25 ¹H NMR (DMSO-D₆, 300 MHz) δ 13.58 (s, 1H), 10.46 (s, 1H), 8.04 (d, 2H), 7.89 (d, 1H), 7.69 (d, 2H), 6.84 (d, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(4-trifluoromethylphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 4-trifluoromethyl-phenylamide (see step (a) above) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M^+) m/z = 418.

1H NMR (CD_3CN , 300 MHz) δ 9.52 (s, 1H), 9.47 (s, 1H), 8.36 (d, 1H), 8.00 (d, 2H), 7.70 (d, 2H), 7.34 (d, 1H), 7.11 (dd, 1H), 6.99 (d, 1H), 6.88 (d, 1H), 6.01 (s, 2H).

Example 76

Pyrazole-1,3-dicarboxylic acid 1-pentylamide 3-(4-trifluoromethylphenylamide)

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 4-trifluoromethylphenylamide (see Example 75(a)) and pentyl isocyanate.

MS (M^+) m/z = 368.

1H NMR ($CDCl_3$, 300 MHz) δ 8.67 (s, 1H), 8.31 (d, 1H), 7.83 (d, 2H), 7.64 (d, 2H), 7.06 (t, 1H), 7.02 (d, 1H), 3.48 (q, 2H), 1.76-1.65 (m, 2H), 1.45-1.36 (m, 4H), 0.98-0.90 (m, 3H).

Example 77

6-{[3-(4-Trifluoromethylphenylcarbonyl)pyrazole-1-carbonyl]amino}hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 4-trifluoromethyl-phenylamide (see Example 75(a)) and ethyl 6-isocyanatohexanoate.

MS (M^+) m/z = 440.

^1H NMR (CDCl_3 , 300 MHz) δ 8.86 (s, 1H), 8.31 (d, 1H), 7.87 (d, 2H), 7.65 (d, 2H), 7.19 (t, 1H), 7.03 (d, 1H), 4.10 (q, 2H), 3.52 (q, 2H), 2.38 (t, 2H), 1.80-1.68 (m, 4H), 1.55-1.43 (m, 2H), 1.23 (t, 3H).

5

Example 78

Pyrazole-1,3-dicarboxylic acid bis(benzo[1,3]dioxol-5-ylamide)

(a) 1H-Pyrazole-3-carboxylic acid benzo[1,3]dioxol-5-ylamide

- 10 The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 3, 4-(methylenedioxy)aniline.

MS (M^+) m/z = 231.

- 15 ^1H NMR ($\text{DMSO}-D_6$, 300 MHz) δ 13.39 (s, 1H), 9.97 (s, 1H), 7.88 (s, 1H), 7.47 (s, 1H), 7.27 (d, 1H), 6.87 (d, 1H), 6.74 (s, 1H), 5.99 (s, 2H).

(b) Pyrazole-1,3-dicarboxylic acid bis(benzo[1,3]dioxol-5-ylamide)

- 20 The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid benzo[1,3]dioxol-5-ylamide (see step (a) above) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M^+) m/z = 394.

- 25 ^1H NMR (CD_3CN , 300 MHz) δ 9.42 (s, 1H), 9.18 (s, 1H), 8.37 (d, 1H), 7.47 (dd, 1H), 7.34 (dd, 1H), 7.17-7.07 (m, 2H), 6.97 (d, 1H), 6.93-6.85 (m, 2H), 6.02 (s, 2H), 6.00 (s, 2H).

Example 79

Pyrazole-1,3-dicarboxylic acid 3-(benzo[1,3]dioxol-5-ylamide) 1-pentylamide

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid benzo[1,3]dioxol-5-ylamide (see Example 78(a)) and pentyl isocyanate.

MS (M^+) m/z = 344.

1H NMR ($CDCl_3$, 300 MHz) δ 8.46 (s, 1H), 8.27 (d, 1H), 7.39 (d, 1H), 7.08 (t, 1H), 6.98 (d, 1H), 6.95 (d, 1H), 6.78 (d, 1H), 5.98 (s, 2H), 3.46 (q, 2H), 1.74-1.63 (m, 2H), 1.43-1.35 (m, 4H), 0.97-0.89 (m, 3H).

Example 80

6-{[3-(Benzo[1,3]dioxol-5-ylcarbamoyl)pyrazole-1-carbonyl]-amino}-hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid benzo[1,3]dioxol-5-ylamide (see Example 78(a)) and ethyl 6-isocyanatohexanoate.

MS (M^+) m/z = 416.

1H NMR ($CDCl_3$, 300 MHz) δ 8.63 (s, 1H), 8.27 (d, 1H), 7.40 (d, 1H), 7.22 (t, 1H), 6.99 (dd, 1H), 6.98 (d, 1H), 6.78 (d, 1H), 5.98 (s, 2H), 4.10 (q, 2H), 3.48 (q, 2H), 2.35 (t, 2H), 1.77-1.64 (m, 4H), 1.52-1.39 (m, 2H), 1.23 (t, 3H).

Example 81

Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(3-chloro-4-fluorophenylamide)

5 (a) 1H-Pyrazole-3-carboxylic acid 3-chloro-4-fluorophenylamide

The sub-title compound was prepared according to the procedure described above in Example 57(a) using dipyrazolo[1,5-a;1',5'-d]pyrazine-4,9-dione (see Example 6(a)) and 3-chloro-4-fluoroaniline.

MS (M^+) m/z = 239.

10 1H NMR (DMSO- D_6 , 300 MHz) δ 13.60 (broad s, 1H), 10.30 (broad s, 1H), 8.09 (dd, 1H), 7.87 (s, 1H), 7.77 (ddd, 1H), 7.48 (t, 1H), 6.80 (s, 1H).

(b) Pyrazole-1,3-dicarboxylic acid 1-(benzo[1,3]dioxol-5-ylamide) 3-(3-chloro-4-fluorophenylamide)

15 The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid 3-chloro-4-fluorophenyl-amide (see step (a) above) and 3,4-(methylenedioxy)phenyl isocyanate.

MS (M^+) m/z = 402.

20 1H NMR ($CDCl_3$, 300 MHz) δ 8.76 (s, 1H), 8.56 (s, 1H), 8.40 (d, 1H), 7.88 (dd, 1H), 7.58 (ddd, 1H), 7.29 (d, 1H), 7.18 (dd, 1H), 7.07 (d, 1H), 6.98 (dd, 1H), 6.85 (d, 1H), 6.04 (s, 2H).

Example 82

25 6-([3-(3-Chloro-4-fluorophenylcarbamoyl)pyrazole-1-carbonyl]amino)hexanoic acid ethyl ester

The title compound was prepared according to the procedure described above in Example 57(b) from 1H-pyrazole-3-carboxylic acid 3-chloro-4-fluorophenyl-amide (see Example 81(a)) and ethyl 6-isocyanatohexanoate.

MS (M^+) m/z = 424.

1H NMR ($CDCl_3$, 300 MHz) δ 8.74 (s, 1H), 8.29 (d, 1H), 7.86 (dd, 1H), 7.58 (ddd, 1H), 7.19 (t, 1H), 7.14 (dd, 1H), 7.00 (d, 1H), 4.09 (q, 2H), 3.50 (q, 2H), 2.37 (t, 2H), 1.79-1.66 (m, 4H), 1.53-1.41 (m, 2H), 1.23 (t, 3H).

5

Example 83

Pyrazole-1,3-dicarboxylic acid 3-(3-chloro-4-fluorophenylamide) 1-pentylamide

The title compound was prepared according to the procedure described above in Example 57(b) from 1*H*-pyrazole-3-carboxylic acid 3-chloro-4-fluorophenyl-amide (see Example 81(a)) and pentyl isocyanate.

MS (M^+) m/z = 352.

1H NMR ($CDCl_3$, 300 MHz) δ 8.53 (s, 1H), 8.30 (d, 1H), 7.83 (dd, 1H), 7.54 (ddd, 1H), 7.14 (dd, 1H), 7.07 (t, 1H), 6.99 (d, 1H), 3.47 (q, 2H), 1.75-1.62 (m, 2H), 1.45-1.34 (m, 4H), 0.98-0.89 (m, 3H).

15

Example 84.

The inhibition of 15-lipoxygenase obtained using the biological test method described above is exemplified by the compounds of the above examples, as listed in the following table:

20

Example 1: 45%

Example 8: 50%


Example 14: 39%

Example 23: 44%

25 Example 26: 45%

Claims

1. A compound of formula I,



wherein

either

- 10 R^1 represents an aryl group or a heteroaryl group, both of which are optionally substituted by one or more substituents selected from G^1 and B^1 , which B^1 group may itself be further substituted by one or more substituents selected from G^2 , Z (provided that Z is not directly attached to an aryl or a heteroaryl group) and B^2 (which B^2 group is optionally further substituted by one or more substituents selected from G^3 , B^3 and Z, provided that Z is not attached to an aryl or a heteroaryl group); and
- 15 R^2 represents H or C_{1-6} alkyl, which latter group is optionally substituted by one or more halo groups;

or

- 20 when R^2 represents C_{1-6} alkyl optionally substituted by halo, R^1 and R^2 may be linked together forming a further 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more substituents selected from G^1 , Z (provided that the ring is not aromatic in nature) and B^1 (which B^1 group is optionally substituted as described above);
- 25

R^3 represents C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, aryl or heteroaryl, all of which groups are optionally substituted by one or more substituents selected from G^{1a} , Z (provided that
 5 Z is not directly attached to an aryl or a heteroaryl group) and B^1 (which B^1 group is optionally substituted as described above);

X represents a direct bond, -O- or -N(R^4)-;

Y represents -C(O)-, -C(S)- or -S(O)₂-;

10

B^1 , B^2 and B^3 independently represent, on each occasion when used above, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, aryl or heteroaryl;

15 G^1 , G^{1a} , G^2 and G^3 independently represent, on each occasion when used above, halo, cyano, -N₃, -NO₂, -ONO₂ or -A¹-R⁴;

wherein A¹ represents a spacer group selected from -C(Z)A²-, -N(R^5)A³-, -OA⁴-, -S- or -S(O)_nA⁵-, in which:

A² represents a single bond, -O-, -S- or -N(R^5)-;

20 A³ represents A⁶, -C(Z)N(R^5)C(Z)N(R^5)-, -C(Z)N(R^5)C(Z)O-, -C(Z)N(R^5)S(O)_nN(R^5)-, -C(Z)S-, -S(O)_n-, -S(O)_nN(R^5)C(Z)N(R^5)-, -S(O)_nN(R^5)C(Z)O-, -S(O)_nN(R^5)S(O)_nN(R^5)-, -C(Z)O-, -S(O)_nN(R^5)- or -S(O)_nO-;

A⁴ represents A⁶, -S(O)_n-, -C(Z)O-, -S(O)_nN(R^5)- or -S(O)_nO-;

25 A⁵ represents a single bond, -N(R^5)- or -O-;

A⁶ represents a single bond, -C(Z)- or -C(Z)N(R^5)-;

Z represents, on each occasion when used above, a substituent connected by a double bond, which is selected from $=O$, $=S$, $=NR^4$, $=NN(R^4)(R^5)$, $=NOR^4$, $=NS(O)_2N(R^4)(R^5)$, $=NCN$, $=CHNO_2$ and $=C(R^4)(R^5)$;

5 R^4 and R^5 independently represent, on each occasion when used above, H or B^4 , which B^4 group is itself optionally substituted by one or more substituents selected from G^4 , Q (provided that Q is not directly attached to an aryl or a heteroaryl group) and B^5 (which B^5 group is itself optionally substituted by one or more substituents selected from G^5 , Q (provided that
10 Q is not directly attached to an aryl or a heteroaryl group) and B^6); or when R^4 and R^5 both represent optionally substituted B^4 groups, then any pair thereof may, for example when present on the same atom or on adjacent atoms, be linked together to form, with those, or other relevant, atoms, a 5- to 7-membered ring, optionally containing 1 to 3 heteroatoms
15 and/or 1 to 3 double bonds, which ring is itself optionally substituted by one or more substituents selected from G^6 , Q (provided that the ring is not aromatic in nature) and B^4 (which B^4 group is optionally substituted as described above);

20 B^4 , B^5 and B^6 independently represent on each occasion when used above. C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8} heterocycloalkyl, aryl or heteroaryl;

G^4 , G^5 and G^6 independently represent on each occasion when used above,
25 halo, cyano, N_3 , $-NO_2$, $-ONO_2$ or $-A^7-R^6$;
wherein A^7 represents a spacer group selected from $-C(Q)A^8-$, $-N(R^7)A^9-$, $-N(R^{7a})A^{9a}-$, $-OA^{10}-$, $-S-$ or $-S(O)_nA^{11}-$, in which:
 A^8 represents a single bond, $-O-$, $-S-$ or $-N(R^7)-$;
 A^9 represents A^{12} , $-C(Q)S-$, $-S(O)_n-$, $-C(Q)O-$, $-S(O)_nN(R^7)-$ or $-S(O)_nO-$;

A^{9a} represents $-C(Q)N(R^7)C(Q)N(R^7)-$, $-C(Q)N(R^7)C(Q)O-$,
 $-C(Q)N(R^7)S(O)_nN(R^7)-$, $-S(O)_nN(R^7)C(Q)N(R^7)-$, $-S(O)_nN(R^7)C(Q)O-$,
 $-S(O)_nN(R^7)S(O)_nN(R^7)-$;

A^{10} represents A^{12} , $-S(O)_n-$, $-C(Q)O-$, $-S(O)_nN(R^7)-$ or $-S(O)_nO-$;

5 A^{11} represents a single bond, $-N(R^7)-$ or $-O-$;

A^{12} represents a single bond, $-C(Q)-$ or $-C(Q)N(R^7)-$;

Q represents, on each occasion when used above, a substituent connected by
a double bond, which is selected from $=O$, $=S$, $=NR^6$, $=NN(R^6)(R^7)$,
10 $=NOR^6$, $=NS(O)_2N(R^6)(R^7)$, $=NCN$, $=CHNO_2$ and $=C(R^6)(R^7)$;

R^6 , R^7 and R^{7a} independently represent, on each occasion when used above,
H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{3-8}
heterocycloalkyl, aryl or heteroaryl, which latter seven groups are
15 optionally substituted by one or more groups selected from halo, C_{1-6} alkyl
(optionally substituted by one or more halo groups), $-N(R^8)R^9$, $-OR^8$,
 $-ONO_2$ and $-SR^8$; or

provided that they do not represent H, any pair of R^6 and R^7 may, for
example when present on the same atom or on adjacent atoms, be linked
20 together to form, with those, or other relevant, atoms, a 5- to 7-membered
ring, optionally containing 1 to 3 heteroatoms and/or 1 to 3 double bonds,
which ring is itself optionally substituted by one or more groups selected
from halo, C_{1-6} alkyl (optionally substituted by one or more halo groups),
 $-N(R^8)R^9$, $-OR^8$, $-ONO_2$ and $-SR^8$;

25 R^8 and R^9 independently represent, on each occasion when used above, H or
 C_{1-6} alkyl, which latter group is optionally substituted by one or more halo
groups; and

n represents, on each occasion when used above, 1 or 2;

or a pharmaceutically-acceptable salt thereof,

5 provided that, when R^2 represents H, Y represents $-C(O)-$ and:

(A) X represents a direct bond and:

- i) R^3 represents phenyl, then R^1 does not represent phenyl, 2-methoxyphenyl, 2-thiazolyl or 6-methyl-2-pyridinyl;
- 10 ii) R^3 represents 4-fluorophenyl, then R^1 does not represent 2-carbomethoxyphenyl, 3-carbomethoxyphenyl or 2,4-dimethylphenyl;
- iii) R^3 represents 2-chlorophenyl, then R^1 does not represent phenyl, 3-bromophenyl or 4-bromophenyl;
- 15 iv) R^3 represents 3-chlorophenyl, then R^1 does not represent phenyl, 2-fluorophenyl, 2-chlorophenyl, 2,3-dichlorophenyl or 2,5-dichlorophenyl;
- v) R^3 represents 4-chlorophenyl, then R^1 does not represent 3-bromophenyl or 4-methoxyphenyl;
- 20 vi) R^3 represents 3-iodophenyl, then R^1 does not represent 2-methoxyphenyl or 2,4-dimethylphenyl;
- vii) R^3 represents 2,4-dichlorophenyl, then R^1 does not represent 4-chlorophenyl or 2,3-dichlorophenyl;
- viii) R^3 represents 3,5-dinitrophenyl, then R^1 does not represent 2,3-dichlorophenyl;
- 25 ix) R^3 represents 2,4-dimethyl-6-oxo-6H-pyran-3-yl, then R^1 does not represent 3-carbomethoxyphenyl;
- x) R^3 represents methyl, then R^1 does not represent 3,4-dichlorophenyl, 2-methoxyphenyl, 2-thiazolyl, 4-methyl-2-pyridinyl, 6-methyl-2-pyridinyl or 4-acetylphenyl;

- xi) R^3 represents ethyl, then R^1 does not represent phenyl, 2,3-dichlorophenyl, 4-methoxyphenyl, 2-carbomethoxyphenyl, 2-thiazolyl or 4-methyl-2-pyridinyl;

(E) X represents -N(H)- and:

- 5 i) R^3 represents phenyl, then R^1 does not represent 4-methoxyphenyl, 2,4-dimethylphenyl or 2-thiazolyl;
- ii) R^3 represents 3-chlorophenyl, then R^1 does not represent 4-methylphenyl;
- 10 iii) R^3 represents 4-chlorophenyl, then R^1 does not represent 3-bromophenyl;
- iv) R^3 represents 3,4-dichlorophenyl, then R^1 does not represent 4-methyl-2-pyridinyl or 6-methyl-2-pyridinyl;
- v) R^3 represents 2'-sulfamoylbiphenyl-4-yl, then R^1 does not represent 5-bromo-2-pyridinyl;
- 15 vi) R^3 represents 1-propyl, then R^1 does not represent phenyl;
- vii) R^3 represents 1-butyl, then R^1 does not represent 4-bromophenyl or 2,4-dimethylphenyl;
- viii) R^3 represents cyclohexyl, then R^1 does not represent 4-methoxyphenyl;

20 (C) X represents -O- and:

- i) R^3 represents phenyl, then R^1 does not represent phenyl or 6-methyl-2-pyridinyl;
- 25 ii) R^3 represents methyl, then R^1 does not represent phenyl, 2-fluorophenyl, 2,4-dimethylphenyl, 4-acetylphenyl or 2-thiazolyl;
- iii) R^3 represents ethyl, then R^1 does not represent phenyl, 2-fluorophenyl, 4-acetylphenyl or 4-methyl-2-pyridinyl;

- iv) R^3 represents 1-butyl, then R^1 does not represent 2-fluorophenyl, 2-methoxyphenyl, 4-methyl-2-pyridinyl or 6-methyl-2-pyridinyl;
- v) R^3 represents 2-butyl, then R^1 does not represent 2-thiazolyl or 4-acetylphenyl;
- vi) R^3 represents 2-methyl-1-propyl, then R^1 does not represent phenyl or 3-nitrophenyl.

2. A compound as claimed in Claim 1, wherein R^1 represents an aryl or heteroaryl group, both of which are optionally substituted as defined in Claim 1.

3. A compound as claimed in Claim 1 or Claim 2, wherein G^1 represents halo, cyano or $-A^1-R^4$.

4. A compound as claimed in any one of the preceding claims, wherein B^1 represents an optionally substituted C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{4-7} heterocycloalkyl, or phenyl, group.

5. A compound as claimed in any one of the preceding claims, wherein G^{1a} represents halo, cyano, $-NO_2$ or $-A^1-R^4$.

6. A compound as claimed in any one of the preceding claims, wherein G^2 represents halo, cyano, $-ONO_2$ or $-A^1-R^4$.

7. A compound as claimed in any one of the preceding claims, wherein B^2 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which are optionally substituted by one or more G^3 and/or B^3 groups.

8. A compound as claimed in any one of the preceding claims, wherein G^3 represents halo, $-\text{ONO}_2$, $-\text{N}(\text{R}^5)(\text{R}^4)$ or $-\text{OR}^4$.

9. A compound as claimed in any one of the preceding claims, wherein
5 B^3 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl.

10. A compound as claimed in any one of the preceding claims, wherein when A^1 represents $-\text{N}(\text{R}^5)\text{A}^3-$, A^3 represents A^6 , $-\text{C}(\text{Z})\text{S}-$, $-\text{S}(\text{O})_n-$, $-\text{C}(\text{Z})\text{O}-$ or $-\text{S}(\text{O})_n\text{N}(\text{R}^5)-$.

10

11. A compound as claimed in any one of Claims 1 to 9, wherein when A^1 represents $-\text{OA}^4-$, A^4 represents A^6 .

12. A compound as claimed in any one of Claims 1 to 9, wherein when
15 A^1 represents $-\text{S}(\text{O})_n\text{A}^5-$, A^5 represents a single bond or $-\text{N}(\text{R}^5)-$.

13. A compound as claimed in any one of Claims 1 to 9, wherein when A^1 represents $-\text{C}(\text{Z})\text{A}^2-$, A^2 represents a single bond, $-\text{O}-$ or $-\text{N}(\text{R}^5)-$.

20

14. A compound as claimed in any one of Claims 1 to 11 or 13 wherein A^1 represents $-\text{C}(\text{Z})\text{A}^2-$, $-\text{N}(\text{R}^5)\text{A}^3-$ or $-\text{OA}^4-$.

15. A compound as claimed in any one of the preceding claims, wherein
25 Z represents $=\text{O}$ or $=\text{NR}^4$.

16. A compound as claimed in any one of the preceding claims, wherein when any pair of R^4 and R^5 are linked together to form a ring, they are optionally substituted with G^6 and/or B^4 .

17. A compound as claimed in any one of the preceding claims, wherein G^4 represents halo, cyano, $-\text{ONO}_2$ or $-\text{A}^7\text{-R}^6$.
- 5 18. A compound as claimed in any one of the preceding claims, wherein B^5 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which are optionally substituted by one or more G^5 and/or B^6 groups.
19. A compound as claimed in any one of the preceding claims, wherein
10 G^5 represents halo, $-\text{ONO}_2$, $-\text{N}(\text{R}^7)(\text{R}^6)$ or $-\text{OR}^6$.
20. A compound as claimed in any one of the preceding claims, wherein B^6 represents C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl.
- 15 21. A compound as claimed in any one of the preceding claims, wherein G^6 represents halo, cyano or $-\text{A}^7\text{-R}^6$.
-
22. A compound as claimed in any one of the preceding claims, wherein A^7 represents $-\text{C}(\text{Q})\text{A}^8$ -, $-\text{N}(\text{R}^7)\text{A}^9$ -, $-\text{OA}^{10}$ -, $-\text{S}$ - or $-\text{S}(\text{O})_n\text{A}^{11}$ -.
- 20 23. A compound as claimed in any one of the preceding claims, wherein when A^7 represents $-\text{N}(\text{R}^7)\text{A}^9$ -, A^9 represents A^{12} , $-\text{C}(\text{Q})\text{S}$ -, $-\text{S}(\text{O})_n$ -, $-\text{C}(\text{Q})\text{O}$ - or $-\text{S}(\text{O})_n\text{N}(\text{R}^7)$ -.
- 25 24. A compound as claimed in any one of Claims 1 to 22, wherein when A^7 represents $-\text{OA}^{10}$ -, A^{10} represents A^{12} .
25. A compound as claimed in any one of Claims 1 to 22, wherein when A^7 represents $-\text{S}(\text{O})_n\text{A}^{11}$ -, A^{11} represents a single bond or $-\text{N}(\text{R}^7)$ -.

26. A compound as claimed in any one of Claims 1 to 22, wherein when A^7 represents $-C(Q)A^8-$, A^8 represents a single bond, $-O-$ or $-N(R^7)-$.

5 27. A compound as claimed in any one of the preceding claims, wherein Q represents $=O$ or $=NR^6$.

28. A compound as claimed in any one of the preceding claims, wherein R^6 , R^7 and R^{7a} independently represent H, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl, all of which groups are optionally substituted by one or more groups selected from halo, C_{1-6} alkyl, $-N(R^8)R^9$, OR^8 and $-ONO_2$.

10

29. A compound as claimed in any one of Claims 1 to 27 wherein when any pair of R^6 and R^7 are linked together to form a ring, that ring is optionally substituted by one or more groups selected from halo, C_{1-6} alkyl (optionally substituted by one or more halo groups), $-N(R^8)R^9$, $-OR^8$ and $-ONO_2$.

15

30. A compound as claimed in any one of the preceding claims, wherein B^4 represents an optionally substituted C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{4-7} heterocycloalkyl, or phenyl, group.

20

31. A compound as claimed in any one of the preceding claims wherein R^4 and/or R^5 independently represent H or C_{1-6} alkyl, which latter group is optionally substituted by one or more fluoro groups.

25

32. A compound as claimed in any one of the preceding claims, wherein X represents a direct bond, $-O-$, $-N(H)-$ or $-N(Me)-$.

33. A compound as claimed in any one of the preceding claims wherein R^2 represents H, methyl or ethyl.

34. A compound as claimed in any one of Claims 1, 32 or 33, wherein R^1 represents an optionally substituted phenyl, naphthyl, pyrrolidinyl, piperidinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, indazolyl, indolyl, indolinyl, isoindolinyl, oxindolyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinoliziny, benzofuranyl, isobenzofuranyl, chromanyl, benzothiophenyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, quinazolinyl, quinoxaliny, 1,3-benzodioxolyl, benzothiazolyl, or benzodioxany, group.

35. A compound as claimed in Claim 34, wherein R^1 represents optionally substituted phenyl, 2-pyridinyl, 3-pyridinyl, 2-thiophenyl, 4-pyrazolyl, 5-isoxazolyl, 1,3-benzodioxolyl, indazolyl, benzothiazolyl, or quinolinyl, group.

36. A compound as claimed in Claim 34 or Claim 35, wherein the optional substituent(s) are selected from halo, cyano, C_{1-6} alkyl (which alkyl group may be linear or branched, and/or substituted by one or more fluoro and/or C_{3-6} cycloalkyl groups), C_{2-6} alkenyl, C_{3-6} cycloalkyl, phenyl, pyrrolidinyl piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, thiomethyl, methylsulfinyl, methylsulfonyl, $-OR^{10}$, $-N(R^{10})R^{11}$, $-C(O)OR^{10}$, $-C(O)R^{10}$, $-C(O)N(R^{10})R^{11}$, $-S(O)_2N(R^{10})R^{11}$ and $-N(R^{10})S(O)_2R^{12}$, wherein R^{10} and R^{11} independently represent H, phenyl, C_{1-6} alkyl (which alkyl group is optionally substituted by one or more fluoro atom), C_{2-6} alkenyl or C_{3-6} cycloalkyl; or R^{10} and R^{11} may be linked together to form, with the nitrogen atom to which they are attached, a 5- to 7-

membered ring, optionally containing one additional heteroatom and optionally substituted with one or more C₁₋₆ alkyl groups, which alkyl groups are themselves optionally substituted by one or more halo groups; and R¹² represents phenyl, C₁₋₆ alkyl (which alkyl group is optionally substituted by one or more fluoro atom), C₂₋₆ alkenyl or C₃₋₆ cycloalkyl.

37. A compound as claimed in Claim 36, wherein the optional substituent(s) are selected from carbomethoxy, methyl, dimethylamino, cyano, chloro, fluoro, trifluoromethyl, bromo, methoxy and trifluoromethoxy.

38. A compound as claimed in any one of Claims 1 or 32 to 37, wherein R³ represents an optionally substituted C₁₋₆ alkyl, C₃₋₆ cycloalkyl, phenyl, naphthyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, indazolyl, indolyl, indolinyl, isoindolinyl, oxindolyl, quinolinyl, 1,2,3,4-tetrahydroquinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, quinoliziny, benzofuranyl, isobenzofuranyl, chromanyl, benzothiophenyl, pyridazinyl, pyrimidinyl, pyrazinyl, indazolyl, benzimidazolyl, quinazolinyl, quinoxaliny, 1,3-benzodioxolyl, benzothiazolyl, or benzodioxany, group.

39. A compound as claimed in Claim 38, wherein R³ represents an optionally substituted C₁₋₆ alkyl, cyclohexyl, phenyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 2-pyrrolyl, 1-naphthyl, 4-piperazinyl, 4-piperidinyl, benzofuranyl, or 1,3-benzodioxolyl, group.

40. A compound as claimed in Claim 38 or Claim 39, wherein the optional substituent(s) are selected from halo, -NO₂, cyano, C₁₋₆ alkyl

(which alkyl group may be linear or branched, and/or optionally substituted with one or more halo, C₁₋₆ alkyl, C₂₋₆ alkenyl and/or C₃₋₆ cycloalkyl, groups, which latter three groups are themselves optionally substituted with one or more halo and/or C₁₋₆ alkyl groups). C₂₋₆ alkenyl (optionally substituted with one or more C₁₋₆ alkyl groups), C₃₋₆ cycloalkyl (optionally substituted with one or more halo groups), phenyl (optionally substituted with one or more halo groups), pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, thiomethyl, methylsulfinyl, methylsulfonyl, =O, -OR¹³, -N(R¹³)R¹⁴, -C(O)OR¹³, -C(O)R¹³, -C(O)N(R¹³)R¹⁴, -S(O)₂N(R¹³)R¹⁴ and -N(R¹³)S(O)₂R¹⁵, wherein R¹³ and R¹⁴ independently represent H, phenyl, C₁₋₆ alkyl (which alkyl group is optionally substituted by one or more fluoro atom), C₂₋₆ alkenyl or C₃₋₆ cycloalkyl; or R¹³ and R¹⁴ may be linked together to form, with the nitrogen atom to which they are attached, a 5- to 7-membered ring, optionally containing one additional heteroatom and optionally substituted with one or more C₁₋₆ alkyl groups, which alkyl groups are themselves optionally substituted by one or more halo groups; and R¹⁵ represents phenyl, C₁₋₆ alkyl (which alkyl group is optionally substituted by one or more fluoro atom), C₂₋₆ alkenyl or C₃₋₆ cycloalkyl.

20

41. A compound as claimed in Claim 40, wherein the optional substituent(s) are selected from methyl, ethyl, ethoxy, trifluoromethyl, fluoro, chloro, iodo, phenyl, 2-chlorophenyl, 4-chlorophenyl, *n*-pentyl, *i*-propyl, nitro, *t*-butyl, -CH₂CH=CHC₈H₁₇, trifluoroacetyl, carbomethoxy, carboethoxy and trifluoromethoxy.

25

42. A compound as claimed in any one of Claims 1 or 32 to 41, wherein R¹ is phenyl, 2-chlorophenyl, 2-chloro-4-fluorophenyl, 3-chloro-4-fluorophenyl, 2,6-dichlorophenyl, 5-chloro-2-cyanophenyl, 2-fluoro-5-

trifluoromethylphenyl, 2-bromo-4-trifluoromethoxyphenyl, 2-methoxy-6-methylphenyl, 3-cyanophenyl, 4-trifluoromethylphenyl, 4-dimethylaminophenyl, 4-carbomethoxyphenyl, 1,3,5-trimethyl-1*H*-pyrazol-4-yl, 3-methylisoxazol-5-yl, 3-pyridinyl, 2-chloro-3-pyridinyl, 3-methyl-2-pyridinyl, 3-carbomethoxythiophen-2-yl or 1,3-benzodioxolyl;

R^2 is hydrogen or methyl;

R^3 is methyl, *n*-butyl, *n*-pentyl, 1-octyl, oleoyl, (1*R*,2*S*,5*R*)-(-)-menthyl, 2-chlorobenzyl, benzyl, phenyl, 3-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluoro-5-iodophenyl, 5-fluoro-2-methylphenyl, 4-*tert*-butylphenyl, 4-pentylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 4-nitrophenyl, 2-ethoxyphenyl, 1-naphthyl, 2-furanyl, 2,5-dimethyl-3-furanyl, 2-carbomethoxy-5-furanyl, 1-methyl-1*H*-pyrrol-2-yl, 3-methyl-2-benzofuranyl, 3-methyl-2-thiophenyl, 1(*N*)-methyl-4-piperazinyl, 1(*N*)-(2,2,2-trifluoroacetyl)piperidin-4-yl, ethylhexanoate or 1,3-benzodioxolyl;

Y is -C(O)-, -C(S)- or -S(O)₂-; and

X is a bond, -N(H)-, -N(Me)-, or -O-.

43. A compound of formula I as defined in any one of Claims 1 to 42, but without the provisos, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

44. A pharmaceutical formulation including a compound of formula I, as defined in any one of Claims 1 to 42, but without the provisos, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

45. A use of a compound of formula I, as defined in any one of Claims 1 to 42, but without the provisos, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease

in which inhibition of the activity of a lipoxxygenase is desired and/or required.

46. A use as claimed in Claim 45 wherein the lipoxxygenase is 15-
5 lipoxxygenase.

47. A use as claimed in Claim 45 or Claim 46, wherein the disease is inflammation and/or has an inflammatory component.

10 48. A use as claimed in Claim 47 wherein the inflammatory disease is asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, an allergic disorder, rhinitis, inflammatory bowel disease, an ulcer, inflammatory pain, fever, atherosclerosis, coronary artery disease, vasculitis, pancreatitis, arthritis, osteoarthritis, rheumatoid arthritis,
15 conjunctivitis, iritis, scleritis, uveitis, a wound, dermatitis, eczema, psoriasis, stroke, diabetes, autoimmune diseases, Alzheimer's disease, multiple sclerosis, sarcoidosis, Hodgkin's disease or another malignancy.

49. A method of treatment of a disease in which inhibition of the activity
20 of a lipoxxygenase is desired and/or required, which method comprises administration of a therapeutically effective amount of a compound of formula I as defined in any one of Claims 1 to 42, but without the provisos, or a pharmaceutically-acceptable salt thereof, to a patient suffering from, or susceptible to, such a condition.

25

50. A combination product comprising:

(A) a compound of formula I as defined in any one of Claims 1 to 42, but without the provisos; and

(B) another therapeutic agent that is useful in the treatment of inflammation,

wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

51. A combination product as claimed in Claim 50 which comprises a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 42, but without the provisos, another therapeutic agent that is useful in the treatment of inflammation, and a pharmaceutically-acceptable adjuvant, diluent or carrier.

52. A combination product as claimed in Claim 50 which comprises a kit of parts comprising components:


(a) a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 42, but without the provisos, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of inflammation in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,

which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.


53. A process for the preparation of a compound as defined in Claim 1, which comprises:

(i) for compounds of formula I in which, when Y is $-S(O)_2-$, X represents a direct bond or $-N(R^4)-$, in which R^4 represents B^4 , reaction of a compound of formula II,



II

wherein R^1 and R^2 are as defined in Claim 1, with a compound of formula III,




III

5 wherein X^a represents a direct bond or $-N(B^4)-$ when Y represents $-S(O)_2-$ or, for all other values of Y , represents X as defined in Claim 1, R^3 and Y are as defined in Claim 1 and L^1 represents a suitable leaving group;

(ii) for compounds of formula I in which X represents a single bond and Y represents $-C(O)-$, reaction of a compound of formula II as defined above

10 with a compound of formula IV,




IV

wherein R^3 is as defined in Claim 1;

(iii) for compounds of formula I in which X represents a direct bond and Y represents a $-C(O)-$ or a $-C(S)-$ group, reaction of a compound of formula II

15 as defined above with a compound of formula V,




V

wherein Y^a represents $-C(O)-$ or $-C(S)-$ and R^3 is as defined in Claim 1;

(iv) for compounds of formula I, in which X represents $-NH-$ and Y represents $-C(O)-$ or $-C(S)-$, reaction of a compound of formula II as

20 defined above with a compound of formula VI,




VI

wherein R^3 is as defined in Claim 1 and Y^a is as defined above;


(v) for compounds of formula I in which Y represents $-C(O)-$ or $-C(S)-$, reaction of a compound of formula II as defined above with:

25 (a) a compound of formula VII,



VII

(b) a compound of formula VIII,



wherein, in both cases, Y^a is as defined above; or

(c) when Y represents -C(O)-, triphosgene,

5 followed by:

(1) for compounds of formula I in which X represents a direct bond, reaction with a compound of formula IX,



wherein M represents a metal such as Mn, Fe, Ni, Cu, Zn, Pd or Ce, or a salt
10 or complex thereof and R³ is as defined in Claim 1;

(2) for compounds of formula I wherein X represents O, reaction with a compound of formula X,



wherein R³ is as defined in Claim 1; or

15 (3) for compounds of formula I wherein X represents -N(R⁴)-, reaction with a compound of formula XI,



wherein R³ and R⁴ are as defined in Claim 1;


(vi) for compounds of formula I in which X represents -N(R⁴)- and R⁴ is
20 other than hydrogen, reaction of a corresponding compound of formula I in which X represents -N(H)- with a compound of formula XII,



wherein R⁴ is as defined in Claim 1 and L¹ is as defined above;

(vii) for compounds of formula I in which Y represents -C(S)-, reaction of a
25 corresponding compound of formula I in which Y represents -C(O)- with a suitable reagent for the conversion of a carbonyl group to a thiocarbonyl group;

(viii) reaction of a compound of formula XIII,



XIII


wherein R^3 , Y and X are as defined in Claim 1, with a compound of formula XIV,



XIV

5 wherein R^1 and R^2 are as defined in Claim 1; or

(ix) reaction of a compound of formula XV,



XV

wherein R^2 , R^3 , Y and X are as defined in Claim 1, with a compound of formula XVI,



XVI

10 wherein L^2 represents a suitable leaving group and R^1 is as defined in Claim 1.

This Page Blank (uspto)

INTERNATIONAL SEARCH REPORT

PCT/GB2004/001054

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/12 C07D405/14 C07D401/14 C07D409/14 C07D409/12
C07D413/12 C07D231/14 A61K31/4155 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/25695 A (NODA YUKA ; OGINO TAKASHI (JP); MANABE TAKASHI (JP); FUJISAWA PHARMACE) 27 May 1999 (1999-05-27) pages 1-2	1-53
A	TIHANYI E ET AL: "PYRAZOLECARBOXYLIC ACID HYDRAZIDES AS ANTIINFLAMMATORY AGENTS. NEW SELECTIVE LIPOXYGENASE INHIBITORS" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 19, no. 5, 1984, pages 433-439, XP000942814 ISSN: 0223-5234 cited in the application the whole document	1-53

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

4 June 2004

Date of mailing of the international search report

15/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

GB2004/001054

Form PCT/ISA/210 (patent family annex) (January 2004)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

—

This Page Blank (uspto)